



**SAN ANTONIO
BREAST CANCER
SYMPOSIUM**

PROGRAM

DECEMBER 10–14, 2013
SAN ANTONIO TEXAS USA
WWW.SABCS.ORG



Dear Colleague,

The UT Health Science Center San Antonio, Baylor College of Medicine, and The American Association for Cancer Research proudly present the 2013 San Antonio Breast Cancer Symposium (SABCS), which will take place December 10-14, 2013, at the Henry B. Gonzalez Convention Center.

Now in its 36th year as the premier conference for basic, translational, and clinical cancer research professionals, SABCS continues to present and discuss the latest breast cancer data from all over the world.

Please note that our registration hours have been expanded, opening at 8:00 am on Tuesday, December 10. That day's program begins at 12 Noon with the popular Career Development Forum. A full schedule of 9 educational sessions runs from 2:00 pm to 7:00 pm.

Noteworthy invited lectures are scheduled on topics ranging from the question of overdiagnosis in screening mammography and local therapy in the molecular era to signatures of mutational processes and psychosocial/survivorship issues.

In response to your comments, this year we bring you the following enhanced services: symposium-wide free wi-fi; abstract book in electronic format; QR codes to download posters; and full lunch breaks.

The popular clinical and basic science forums will provide opportunities for lively discussion. Poster sessions continue through our final day (Saturday) in order to include the many interesting submissions received this year, and special poster sessions reporting ongoing clinical trials return.


The Year in Review will again be presented on our final day. This compilation and contextualization of the year's most important breast cancer science, presented by leading authorities, has become a "can't miss" event. Be sure to plan your travel so that you can attend!

We hope that you will be able to attend and contribute to this excellent international forum for state-of-the-art information on breast cancer.

Sincerely,



Peter M. Ravdin, MD, PhD
Ruth McLean Bowman Bowers Chair for
Breast Cancer Research & Treatment
Director, Breast Cancer Program
UT Health Science Center San Antonio
San Antonio, Texas



C. Kent Osborne, MD
Professor of Medicine and Molecular and
Cellular Biology
Director, Dan L. Duncan Cancer Center
Director, Lester and Sue Smith Breast Center
Baylor College of Medicine
Houston, Texas



Carlos L. Arteaga, MD
Professor of Medicine and Cancer Biology
Associate Director for Clinical Research
Director, Breast Cancer Program
Vanderbilt-Ingram Cancer Center
Vanderbilt University
Nashville, Tennessee



Abstracts Online	17	Registration Contact Form, Group	26
Accreditation	14	Registration, Exhibitor	15
Badges	14	Registration Form, Career Development Forum	32
Climate & Comfort	14	Registration Form, Advance	28–29
Committees	18	Registration Form, Press/Media	30
Exhibit Hours	15	Registration Highlights	15
Exhibitors	Inside Back Cover	Registration Hours	15
Food & Beverages	14	Registration Instructions, General	24
History	13	Registration Instructions, Group	25
Hotel Rates	20	Registration On Site	15
Hotel Map & Information	19	Registration, Press/Media	15
Hotel Instructions	21	Registration, Spouse/Guest	15
Hotel Request Form	22	San Antonio Sights	17
Important Dates 2013	17	Schedule At A Glance	1
Information Boards	17	Slides Online	17
Internet Café	16	Special Assistance	15
Literature Displays	16	Supporters	Inside Back Cover
Location	14	Symposium Contact Information	17
Mobile App	17	Symposium Information	14–17
Posters Online	17	Symposium Objective	14
Program	2–12	Transportation	16
Proof of Attendance	14	Webcast	17
Registration Cancellations & Refunds	16		

MEETING SITE

Henry B. Gonzalez Convention Center
200 E. Market Street, San Antonio, TX 78205

FUTURE SYMPOSIUM MEETING DATES

- December 9–13, 2014 37th Annual SABCS
- December 8–12, 2015 38th Annual SABCS
- December 6–10, 2016 39th Annual SABCS

SCHEDULE AT A GLANCE

Tuesday 12/10/13	Program Slots	Wednesday 12/11/13	Thursday 12/12/13	Friday 12/13/13	Saturday 12/14/13
	7:00				
	7:15				
Registration Opens 8 am– 7 pm	7:30				
	7:45				
	8:00	Welcome	Poster Session 2	Poster Session 4	Poster Session 6
	8:15	Plenary 1 <i>H Gilbert Welch</i>			
	8:30		Plenary 2 <i>Michael Gnant</i>	Plenary 3 <i>Leslie Fallowfield</i>	
Career Development Forum 12:00 pm–1:45 pm	8:45				
	9:00				
	9:15				
	9:30	General Session 1	General Session 3	General Session 5	Year in Review Lectures <i>Basic - Lewis Chodosh</i> <i>Transl - Charles Perou</i> <i>Early BC - Joseph Sparano</i> <i>Adv BC - Stephen Johnston</i>
	9:45				
	10:00				
Educational Sessions 1 2:00–3:30 pm <i>Target DNA damage resp.</i> <i>Mgt premalig / prevention</i> <i>Clinical 101</i>	10:15				
	10:30				
	10:45				
	11:00	McGuire Lecture <i>Monica Morrow</i>	AACR Dist Lect <i>Michael Stratton</i>	AACR Outstdg Inv <i>TBA</i>	
	11:15				
	11:30				
	11:45				
	12:00	Lunch & Exhibits	Lunch & Exhibits	Lunch & Exhibits	
	12:15				
	12:30				
	12:45				
	1:00	Clin & Basic Forums <i>Surg mgt after pre-op Rx</i> <i>Stem cells</i>	Case Disc & Basic Forum <i>Case discussion 1</i> <i>Cancer metabolism</i>	Case Disc & Basic Forum <i>Case discussion 2</i> <i>Migration/metastasis</i>	
	1:15				
	1:30				
Educational Sessions 2 3:45–5:15 pm <i>Adjuvant decision</i> <i>Basic Sci 101</i> <i>Global trends</i>	1:45				
	2:00				
	2:15	Komen Brinker Lectures <i>Mills & Perez</i>	Minisymposium 1 <i>Adoptive T-cell therapy</i>	Minisymposium 2 <i>HER2</i>	
	2:30				
	2:45				
	3:00				
	3:15				
	3:30				
	3:45				
Educational Sessions 3 5:30–7:00 pm <i>Predictive imaging</i> <i>Inflammatory br cancer</i> <i>Mgt metastatic BC / QOL</i>	4:00	General Session 2	General Session 4	General Session 6	
	4:15				
	4:30				
	4:45				
	5:00				
	5:15				
	5:30	Poster Session 1	Poster Session 3	Poster Session 5	
	5:45	PD1, PD2	PD3, PD4	PD5, PD6	
	6:00	Ongoing Trials 1	Ongoing Trials 2	Ongoing Trials 3	
	6:15				
	6:30				
	6:45				
	7:00				

For Exhibit Hours See Page 15

2013 SAN ANTONIO BREAST CANCER SYMPOSIUM

PROGRAM SCHEDULE

(AT PRESS TIME)

Refer to www.sabcs.org for the most current information.

Room Locations

Exhibit Halls A, B, C & D: Street Level
Ballrooms A & B: Street Level
Bridge Hall: Street Level
Room 214: Concourse (2nd) Level

TUESDAY, DECEMBER 10, 2013

8:00 am–7:00 pm

REGISTRATION – Bridge Hall

Pre-registered attendees can obtain materials. Those who have not yet registered may do so.

12:00 pm–1:45 pm

CAREER DEVELOPMENT FORUM: A NETWORKING SESSION FOR YOUNG INVESTIGATORS – Room 214

Networking and career development opportunities for early career scientists. The session is open to early-career scientists, defined as graduate students, postdoctoral or clinical fellows, or medical students and residents, who are registered attendees of the SABCS. Space in the workshop is limited to 300 participants; registrations will be accepted on a first-come, first-served basis and is free of charge.

Please complete the registration form on page 32 in order to attend.

2:00 pm–7:00 pm

THE EDITHA KAPOOR BREAST CANCER EDUCATIONAL SESSIONS – Street Level – Ballrooms A & B and Exhibit Hall D

*Supported by The John and Editha Kapoor Charitable Foundation
and Supported in part by an educational grant from
Susan G. Komen for the Cure®*

Updates on advances in key areas and in technologies available for translational research. Many of the sessions will provide attendees with a better understanding of the background leading up to talks they will hear in the succeeding days, and some of the techniques that will be used. The presentations should also provide researchers with ideas and techniques to be considered for their own studies.

2:00 pm–3:30 pm

DNA Damage Response as a Target of Therapy – Ballroom A

Moderator: Rong Li, PhD
UT Health Science Center San Antonio
San Antonio, TX

2:00 pm

Targeting ATR and the replication stress response

David Cortez, PhD
Vanderbilt University School of Medicine
Nashville, TN

2:30 pm

Mechanisms that maintain genome stability

Andre Nussenzweig, PhD
National Institutes of Health
Bethesda, MD

3:00 pm

Targeting homologous recombination: Translational studies of CDK and PARP inhibitors

Geoffrey I. Shapiro, MD, PhD
Dana-Farber Cancer Institute
Boston, MA

2:00 pm–3:30 pm

Management of Premalignant Disease & Breast Cancer Prevention – Ballroom B

Moderator: Powel H. Brown, MD, PhD
UT MD Anderson Cancer Center
Houston, TX

2:00 pm

Pathology and biology of early lesions

Stuart J. Schnitt, MD
Beth Israel Deaconess Medical Center and
Harvard Medical School
Boston, MA

2:30 pm

Who should receive preventive therapy?

Jack Cuzick, PhD
Queen Mary University of London
London, UNITED KINGDOM

3:00 pm

Breast SERMs and AIs - Prevention of all types of breast cancer

Powel H. Brown, MD, PhD
UT MD Anderson Cancer Center
Houston, TX

2:00 pm–3:30 pm

Clinical 101: Understanding the Basics of Breast Cancer Diagnosis, Treatment and Clinical Trials Research – Exhibit Hall D

Moderator: Andrea Richardson, MD, PhD
Dana-Farber Cancer Institute
Boston, MA

2:00 pm

The pathology of breast cancer

Jane Elizabeth Brock, MBBS, PhD
Brigham & Women's Hospital
Boston, MA

2:30 pm

Breast cancer in 2013: An overview of systemic and local therapies

Carey K. Anders, MD
University of North Carolina at Chapel Hill
Chapel Hill, NC

3:00 pm

Clinical trial endpoints: Selection, analysis and interpretation

Elizabeth Garrett-Mayer, PhD
Medical University of South Carolina
Charleston, SC

3:45 pm–5:15 pm

Basic Science 101 – Ballroom A

Moderator: Suzanne A.W. Fuqua, PhD
Baylor College of Medicine
Houston, TX

3:45 pm

Genomics variation underlying breast cancer heterogeneity

Laura J. van 't Veer, PhD
University of California San Francisco
San Francisco, CA

4:15 pm

Targeting cell signaling in breast cancer

Douglas Yee, MD
University of Minnesota
Minneapolis, MN

4:45 pm

Understanding nuclear receptor in breast cancer

Suzanne A.W. Fuqua, PhD
Baylor College of Medicine
Houston, TX

3:45 pm–5:15 pm

Global Trends in Breast Cancer Incidence and Mortality – Ballroom B

Moderator: Ismail Jatoi, MD, PhD, FACS
UT Health Science Center San Antonio
San Antonio, TX

3:45 pm

Trends in breast cancer incidence and mortality in developing countries

Peggy Porter, MD
University of Washington
Seattle, WA

4:10 pm

Divergent incidence trends in breast cancer subtypes

William F. Anderson, MD, MPH
National Cancer Institute
Rockville, MD

4:35 pm

Declines in breast cancer mortality in the industrialized countries: What is behind it?

Donald A. Berry, PhD
UT MD Anderson Cancer Center
Houston, TX

5:00

Q&A

3:45 pm–5:15 pm

Individualized Adjuvant Decision Making – Exhibit Hall D

Moderator: Peter M. Ravdin, MD, PhD
UT Health Science Center San Antonio
San Antonio, TX

3:45 pm

Adjuvant chemotherapy in the elderly: Making the right decision

Hyman B. Muss, MD
University of North Carolina at Chapel Hill
Chapel Hill, NC

4:15 pm

The impact of biological age

Alistair Ring, MRCP, MD
Brighton & Sussex Medical School
Brighton, UNITED KINGDOM

4:45 pm

Integration of the tumor, treatment, and patient elements

Peter M. Ravdin, MD, PhD
UT Health Science Center San Antonio
San Antonio, TX

5:30 pm–7:00 pm

Inflammatory Breast Cancer: Diagnosis, Treatment, and Biology – Ballroom A

Moderator: Wendy A. Woodward, MD, PhD
UT MD Anderson Cancer Center
Houston, TX

5:30 pm

Diagnostic challenges, epidemiology, and updates in the search for IBC signaling determinants

Sofia D. Merajver, MD, PhD
University of Michigan
Ann Arbor, MI

6:00 pm

Multidisciplinary management and evolving therapies

Massimo Cristofanilli, MD
Thomas Jefferson University
Philadelphia, PA

6:30 pm

Radiation therapy, stem cells, and the microenvironment

Wendy A. Woodward, MD, PhD
UT MD Anderson Cancer Center
Houston, TX

5:30 pm–7:00 pm

Predicting Tumor Response by Functional Imaging – Ballroom B

Moderator: Douglas Yee, MD
University of Minnesota
Minneapolis, MN

5:30 pm

Optical imaging strategies for probing signal transduction pathways in vivo

David Piwnica-Worms, MD, PhD
Washington University
St Louis, MO

6:00 pm

PET imaging as a functional predictive biomarker

David Mankoff, MD, PhD
University of Pennsylvania
Philadelphia, PA

6:30 pm

MR imaging for predicting response to neoadjuvant treatment

Nola Hylton, PhD
University of California, San Francisco
San Francisco, CA

5:30 pm–7:00 pm

Metastatic Breast Cancer: An Update on Management and Supportive Care - Exhibit Hall D

Moderator: Mothaffar Rimawi, MD
Baylor College of Medicine
Houston, TX

5:30 pm

Update on management of ER positive metastatic breast cancer

Harold J. Burstein, MD, PhD
Dana-Farber Cancer Institute
Boston, MA

5:55 pm

Update on management of triple negative metastatic breast cancer

Lisa A. Carey, MD
University of North Carolina
Chapel Hill, NC

6:20 pm
Symptom management and quality of life in metastatic breast cancer

Polly Niravath, MD
 Baylor College of Medicine
 Houston, TX

6:45 pm
Q&A

WEDNESDAY, DECEMBER 11, 2013

7:00 am–5:15 pm

REGISTRATION – Bridge Hall

7:00 am–8:00 am

CONTINENTAL BREAKFAST – Exhibit Hall C

8:00 am–8:15 am

WELCOME – Exhibit Hall D

Opening Remarks

8:15 am–8:45 am

PLENARY LECTURE 1 – Exhibit Hall D

Screening Mammography and Overdiagnosis

H. Gilbert Welch, MD, MPH
 Dartmouth Institute for Health Policy & Clinical Practice
 Thetford, VT

8:45 am–11:15 am

GENERAL SESSION 1 – Exhibit Hall D

8:45 am S1-01 The association between event-free survival and pathological complete response to neoadjuvant lapatinib, trastuzumab or their combination in HER2-positive breast cancer. Survival follow-up analysis of the NeoALTTO study (BIG 1-06)

Piccart-Gebhart M, Holmes AP, de Azambuja E, Di Cosimo S, Swaby R, Untch M, Jackisch C, Lang I, Smith I, Boyle F, Xu B, Barrios C, Gelber R, Eidtmann H, Baselga J. Jules Bordet Institute, Brussels, Belgium; Frontier Science (Scotland) Ltd, Kincaig, Kingussie, United Kingdom; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; GlaxoSmithKline, United States; Academic Hospital of the University Charite, Germany; Klinikum Offenbach, Germany; National Institute of Oncology, Hungary; Royal Marsden Hospital and Institute of Cancer Research, London, United Arab Emirates; Patricia Ritchie Centre for Cancer Care and Research, Mater Hospital North Sydney and University of Sydney, Australia; Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China; PUCRS School of Medicine, Porto Alegre, Belgium; Dana-Farber Cancer Institute, Boston; University Hospital, Kiel, Germany; Memorial Sloan Kettering Cancer Center, New York.

9:00 am S1-02 Final analysis of a phase II 3-arm randomized trial of neoadjuvant trastuzumab or lapatinib or the combination of trastuzumab and lapatinib, followed by six cycles of docetaxel and carboplatin with trastuzumab and/or lapatinib in patients with HER2+ breast cancer (TRIO-US B07)

Hurvitz S, Miller JM, Dichmann R, Perez AT, Patel R, Zehngbot LM, Allen H, Bosserman LD, DiCarlo BA, Kennedy A, Giuliano A, Calfa CJ, Molthrop DC, Mani A, Dering J, Wang H-J, Adams B, Martinez D, Chen H-W, Zoeller J, Brugge JS, Slamon DJ. University of California, Los Angeles, CA; Olive View Medical Center, Sylmar, CA; Central Coast Medical Oncology, Santa Maria, CA; Memorial Cancer Institute, Hollywood, FL; Comprehensive Blood and Cancer Center, Bakersfield, CA; Hematology Oncology Consultants, PA, Orlando, FL; Comprehensive Cancer Center of Nevada, Las Vegas, NV; Wilshire Oncology Medical Group, Rancho Cucamonga, CA; Coastal Integrative Cancer Care, San Luis Obispo, CA; Cedars Sinai Medical Center, Los Angeles, CA; Harvard Medical School, Boston, MA.

9:15 am S1-03. Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer

Slamon DJ, Swain SM, Buyse M, Martin M, Geyer CE, Im Y-H, Pienkowski T, Kim S-B, Robert NJ, Steger G, Crown J, Verma S, Eiermann W, Costantino JP, Im S-A, Mamounas EP, Schwartzberg L, Paterson A, Mackey JR, Provencher L, Press MF, Thirlwell M, Bee-Munteanu V, Henschel V, Crepelle-Flechas A, Wolmark N. UCLA, Los Angeles, CA; MedStar Washington Hospital Center, Washington, MD; IDDI, Louvain-la-Neuve, Belgium; Samsung Medical Center, Seoul, Korea; Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; Virginia Commonwealth University, Richmond, VA; Asan Medical Center, Seoul, Korea; US Oncology Research, Fairfax, VA; ABCSG, Wien, Austria; ICORG, Dublin, Ireland; RotkreuzKlinikum, Munchen, Germany; GEICAM, Madrid, Spain; Cross Cancer Institute, Edmonton, AB, Canada; USC Norris Comprehensive Cancer Center, Los Angeles, CA; F. Hoffmann-La Roche Ltd, Basel, Switzerland; NSABP, Pittsburgh, PA; Seoul National University College of Medicine, Seoul, Korea; Ottawa Hospital Regional Cancer Centre, Ottawa, ON, Canada; ACORN Research, Memphis, TN; Tom Baker Cancer Centre, Calgary, AB, Canada; CHA Universitaire de Quebec Hopital du St-Sacrement, Quebec City, QC, Canada; TRIO, Edmonton, Canada; Montreal General Hospital, Montreal, QC, Canada; MD Anderson Cancer Center Orlando, Orlando, FL; Allegheny Cancer Center, Pittsburgh, PA; University of Pittsburgh, Pittsburgh, PA.

9:30 am S1-04. A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC)

Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, Hudis CA, Krop IE, Burstein HJ, Winer EP. Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan Kettering Cancer Center, New York, NY; Sarah Cannon Research Institute, Nashville, TN; Massachusetts General Hospital, Boston, MA; Duke University, Durham, NC; Loyola University, Maywood, IL; University of California, San Francisco, CA; Washington University, St. Louis, MO; Long Island Jewish Medical Center, New Hyde Park, NY; Johns Hopkins University, Baltimore, MD; University of North Carolina, Chapel Hill, NC.

9:45 am S1-05. Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC)

Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, Brown DN, Kellokumpu-Lehtinen P-L, Bono P, Kataja V, Desmedt C, Piccart-Gebhart MJ, Loibl S, Untch M, Denkert C, Smyth MJ, Joensuu H, Sotiriou C. Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Gustave Roussy, Villejuif, France; Institut Jules Bordet, Brussels, Belgium; Tampere University Hospital, Tampere, Finland; Cancer Center, Kuopio University Hospital, Kuopio, Finland; German Breast Group, Neu-Isenburg, Germany; Helios Klinikum Berlin Buch, Berlin, Germany; Queensland Institute of Medical Research, Herston, Queensland, Australia; Helsinki University Central Hospital, Helsinki, Finland.

10:00 am S1-06. Increased tumor-associated lymphocytes predict benefit from addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer in the GeparSixto trial (GBG 66)

Denkert C, Loibl S, Salat C, Sinn BV, Schem C, Endris V, Klare P, Schmitt WD, Blohmer J-U, Weichert W, Tesch H, Darb-Esfahani S, Kümmel S, Sinn P, Stenzinger A, Jackisch C, Dietel M, Reimer T, Loi S, Mehta K, Gade S, Untch M, von Minckwitz G. Institute of Pathology, Charité Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Hämato-Onkologische Schwerpunktpraxis, Munich, Germany; University of Kiel, Kiel, Germany; Institute of Pathology, University of Heidelberg, Heidelberg, Germany; Praxisklinik für Gynäkologie, Berlin, Germany; Sankt Gertrauden Hospital, Breast Center, Berlin, Germany; Onkologische Gemeinschaftspraxis, Frankfurt, Germany; Klinikum Essen-Mitte, Essen, Germany; Klinik für Gynäkologie und Geburtshilfe, Klinikum Offenbach, Offenbach, Germany; Universitätsfrauenklinik am Klinikum Südstadt, Rostock, Germany; Peter MacCallum Cancer Centre, Melbourne, Australia; Brustzentrum Berlin-Buch, Helios Kliniken, Berlin-Buch, Germany; German Cancer Consortium (DKTK), Germany.

10:15 am S1-07. Prognostic value of tumor-infiltrating lymphocytes (TILs) in two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199

Adams S, Gray R, Demaria S, Goldstein LJ, Perez EA, Shulman LN, Martino S, Davidson NE, Sledge GW, Sparano JA, Badve SS. Eastern Co-operative Oncology Group; North Central Cancer Treatment Group; Cancer and Leukemia Group B; Southwest Oncology Group.

10:30 am S1-08. Discussant (S1-05 to S1-07)

10:45 am S1-09. MRI screening of women at average risk of breast cancer

Schrading S, Strobel K, Kuhl CK. University Hospital RWTH, Aachen, Germany.

11:00 am S1-10. Disparities in the estimates of benefits and harms from mammography: Are the numbers really different?

Smith RA, Duffy S, Chen TH-H, Yen AMF, Tabar L. American Cancer Society, Atlanta, GA; Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, United Kingdom; Graduate Institute of Epidemiology and Preventive Medicine, National Taiwan University, Taipei, Taiwan; School of Oral Hygiene, Taipei Medical University, Taipei, Taiwan; Falun Central Hospital, Falun, Sweden.

11:15 am–12:00 pm

WILLIAM L. MCGUIRE MEMORIAL LECTURE – Exhibit Hall D

Local Therapy in the Molecular Era: Relevant or Relic?

Monica Morrow, MD, FACS
Memorial Sloan-Kettering Cancer Center
New York, NY

12:00 pm–1:00 pm

LUNCH AND EXHIBITS

1:00 pm–2:00 pm

CLINICAL SCIENCE FORUM – Ballroom A

Management of the Axilla After Neoadjuvant Systemic Therapy

Moderator: Richard L. Crownover, MD, PhD
UT Health Science Center San Antonio
San Antonio, TX

1:00 pm

The role of sentinel lymph node biopsy before versus after neoadjuvant chemotherapy

Lisa A. Newman, MD, MPH, FACS
University of Michigan Comprehensive Cancer Center
Ann Arbor, MI

1:30 pm

Local-regional management issues for the radiation oncologist in the neoadjuvant chemotherapy setting

Barbara Fowble, MD, FACP, FASTRO
University of California San Francisco
San Francisco, CA

1:00 pm–2:00 pm

BASIC SCIENCE FORUM – Ballroom B

Therapeutic Implications of Cancer Stem Cells

Moderator: Jeffrey M. Rosen, PhD
Baylor College of Medicine
Houston, TX

1:00 pm

Genetic and non-genetic mechanisms contribute to long-term clonal growth dynamics and therapy resistance

John E. Dick, PhD
Ontario Cancer Institute
Toronto, CANADA

1:30 pm

Moving breast cancer stem cell therapies to the clinic

Max S. Wicha, MD
University of Michigan Comprehensive Cancer Center
Ann Arbor, MI

2:15 pm–3:15 pm

SUSAN G. KOMEN FOR THE CURE® BRINKER AWARDS FOR SCIENTIFIC DISTINCTION LECTURES – Exhibit Hall D

The Basic Science Award is presented to a researcher whose scientific discoveries or novel technologies have added substantively to our understanding of the basic biology of breast cancer and the intrinsic molecular processes that drive the disease, and/or whose work has bridged the gap between basic research and patient care. This year the award is being presented to:

Gordon B. Mills, MD, PhD
University of Texas MD Anderson Cancer Center
Houston, TX

The Clinical Research Award is presented to a clinical or translational researcher who has advanced the identification of new prevention, detection or treatment approaches for breast cancer and promoted their incorporation into clinical care. This year the award is being presented to:

Edith A. Perez, MD
Mayo Clinic
Jacksonville, FL

3:15 pm–5:00 pm

GENERAL SESSION 2 – Exhibit Hall D

3:15 pm

S2-01. The PRIME 2 trial: Wide local excision and adjuvant hormonal therapy ± postoperative whole breast irradiation in women ≥ 65 years with early breast cancer managed by breast conservation

Kunkler IH, Williams LW, Jack W, Canney P, Prescott RJ, Dixon MJ. University of Edinburgh, Edinburgh, United Kingdom; Edinburgh Cancer Centre, Edinburgh, United Kingdom; Beatson Oncology Centre, Glasgow, United Kingdom.

3:30 pm

S2-02. Surgical removal of primary tumor and axillary lymph nodes in women with metastatic breast cancer at first presentation: A randomized controlled trial

Badwe R, Parmar V, Hawaldar R, Nair N, Kaushik R, Siddique S, Navale A, Budrukkar A, Mittra I, Gupta S. Tata Memorial Centre, Mumbai, Maharashtra, India.

3:45 pm S2-03. Early follow up of a randomized trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer; Turkish study (protocol MF07-01)

Soran A, Ozmen V, Ozbas S, Karanlik H, Muslumanoglu M, Igci A, Canturk Z, Utkan Z, Ozaslan C, Evrensel T, Uras C, Aksaz E, Soyder A, Ugurlu U, Col C, Cabioglu N, Bozkurt B, Dagoglu T, Uzunkoy A, Dulger M, Koksal N, Cengiz O, Gulluoglu B, Unal B, Atalay C, Yildirim E, Erdem E, Salimoglu S, Sezer A, Koyuncu A, Gurleyik G, Alagol H, Ulufi N, Berberoglu U, Kennard E, Kelsey S, Lembersky B. Turkish Federation of Societies for Breast Diseases, Istanbul, Turkey.

4:00 pm S2-04. Discussant (S2-02 to S2-03)

4:15 pm S2-05. 10-yr follow-up results of occult detected sentinel node disease: NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients

Julian TB, Anderson SJ, Krag DN, Weaver DL, Costantino JP, Ashikaga T, Harlow SP, Mamounas EP, Wolmark N. National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; Allegheny General Hospital/West Penn Allegheny Health System, Pittsburgh, PA; National Surgical Adjuvant Breast and Bowel Project Biostatistical Center, Pittsburgh, PA; University of Vermont, Burlington, VT; MD Anderson Cancer Center Orlando, Orlando, FL.

4:30 pm S2-06. Extracellular matrix stiffness modulates tissue inflammation to promote breast tumor aggression

Acerbil I, Hwang S, Munson J, Au A, Zheng S, Yu H, Mouw J, Lakins J, Swartz M, Shi Q, Liphardt J, Ruffell B, Coussen LM, Yunn-Yi C, Weaver VM. UCSF, San Francisco, CA; Duke University, Durham, NC; École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland; University of California, Berkeley, CA; Oregon Health and Science University, OR.

4:45 pm S2-07. An international Ki67 reproducibility study: Harmonizing scoring methodology

Nielsen TO, Polley M-YC, on behalf of the International Ki67 in Breast Cancer Working Group of BIG-NABCG. University of British Columbia, Vancouver, BC, Canada; National Cancer Institute, Bethesda, MD; BIG-NABCG Collaboration

5:00 pm–7:00 pm

POSTER DISCUSSION 1

PI3K/TOR PATHWAY – Ballroom A

5:00 pm–7:00 pm

POSTER DISCUSSION 2

BODY MASS, EXERCISE, AND BREAST CANCER – Ballroom B

5:00 pm–7:00 pm

POSTER SESSION 1 & reception – Exhibit Halls A–B

Detection and Diagnosis

- P1-01 Axillary Staging and Sentinel Nodes
- P1-02 Diagnostic Pathology
- P1-03 Circulating Markers
- P1-04 Circulating Tumor Cells

Tumor Cell and Molecular Biology

- P1-05 Mammary Development and Differentiation
- P1-06 Microenvironment / Stromal-Epithelial Interactions
- P1-07 Epithelial-Mesenchymal Transition

Prognosis and Response Prediction

- P1-08 Response Predictive Factors

Psychosocial, Quality of Life, and Educational Aspects

- P1-09 Disparities and Barriers to Care
- P1-10 Advocacy
- P1-11 Doctor-Patient Communication
- P1-12 Education

Treatment

- P1-13 Adjuvant Endocrine Therapy
- P1-14 Advanced Endocrine Therapy
- P1-15 Neoadjuvant Endocrine Therapy
- P1-16 Bone Metastases
- P1-17 Male Breast Cancer

Ongoing Clinical Trials 1

- OT1-1 HER2
- OT1-2 Response Prediction
- OT1-3 Circulating Tumor Cells
- OT1-4 New Agents

7:30 pm–9:30 pm

OPEN SATELLITE EVENT presented by Research To Practice – Marriott Rivercenter

Beyond the Guidelines: Clinical Investigators Provide Their Perspectives on Current Strategies and Ongoing Research in the Management of Breast Cancer

THURSDAY, DECEMBER 12, 2013

7:00 am–5:15 pm

REGISTRATION – Bridge Hall

7:30 am–9:00 am

POSTER SESSION 2 & continental breakfast – Exhibit Halls A–B

Detection and Diagnosis

- P2-01 Breast Imaging – Mammography
- P2-02 Breast Imaging – MRI
- P2-03 Breast Imaging – Other
- P2-04 Screening

Tumor Cell and Molecular Biology

- P2-05 Animal Models
- P2-06 Epigenetics
- P2-07 Genetics – Germline
- P2-08 Genetics – Somatic
- P2-09 New Drugs and Mechanisms

Prognosis and Response Prediction

- P2-10 Prognostic Factors and Biomarkers – Preclinical
- P2-11 Prognostic Factors and Biomarkers – Clinical

Epidemiology, Risk, and Prevention

- P2-12 Familial Breast Cancer – Genetic Testing
- P2-13 Familial Breast Cancer – Molecular Genetics
- P2-14 Risk Factors and Modeling

Treatment

- P2-15 Adjuvant Therapy – Targeted
- P2-16 Advanced Therapy – Targeted
- P2-17 Signal Transduction Inhibitors
- P2-18 Surgery
- P2-19 Reconstruction

9:00 am–9:30 am

PLENARY LECTURE 2 – Exhibit Hall D

Adjuvant Bisphosphonate Therapy in Breast Cancer

Michael Gnant, MD, FACS
Medical University of Vienna
Vienna, AUSTRIA

9:30 am–11:30 am

GENERAL SESSION 3 – Exhibit Hall D

- 9:30 am S3-01. First results of the International breast cancer intervention study II (IBIS-II): A multicentre prevention trial of anastrozole versus placebo in postmenopausal women at increased risk of developing breast cancer**
Cuzick J, Sestak I, Forbes JF, Cawthorn S, Roche N, Mansel RE, von Minckwitz G, Bonanni B, Palva T, Howell A. Centre for Cancer Prevention, Queen Mary University, London, United Kingdom; Newcastle Mater Hospital, Newcastle, Australia; Breast Care Centre, Southmead Hospital, Bristol, United Kingdom; Royal Marsden Hospital, London, United Kingdom; University of Wales College of Medicine, Cardiff, United Kingdom; German Breast Group, Frankfurt, Neu-Isenburg, Germany; European Institute of Oncology, Milan, Italy; Pirkanmaa Cancer Society, Tampere, Finland; Paterson Institute for Cancer Research, Manchester, United Kingdom.
- 9:45 am S3-02. Associations between baseline patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor (AI) therapy**
Henry NL, Kidwell K, Hayes DF, Storniolo AM, Flockhart DA, Stearns V, Clauw D, Williams DA. University of Michigan; Indiana University; Johns Hopkins University; for the COBRA Investigators.
- 10:00 am S3-03. Randomized trial of exercise vs. usual care on aromatase inhibitor-associated arthralgias in women with breast cancer: The hormones and physical exercise (HOPE) study**
Irwin ML, Cartmel B, Gross C, Ercolano E, Fiellin M, Capozza S, Rothbard M, Zhou Y, Harrigan M, Sanft T, Schmitz K, Neogi T, Hershman D, Ligibel J. Yale University, New Haven, CT; University of Pennsylvania, Philadelphia, PA; Boston University, Boston, MA; Columbia University, New York, NY; Dana Farber Cancer Institute, Boston, MA.
- 10:15 am S3-04. The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early stage breast cancer**
Hershman DL, Tsui J, Meyer JW, Glied S, Wright JD, Neugut AI. Columbia University Medical Center, New York, NY; Mailman School of Public Health, New York, NY; OptumInsight.
- 10:30 am S3-05. Patient-derived xenograft study reveals endocrine therapy resistance of ER+ breast cancer caused by distinct ESR1 gene aberrations**
Shao J, Li S, Crowder RJ, Kitchens RT, Johnson SN, Goncalves R, Phommaly C, Griffith OL, Maher C, Perou CM, Mardis ER, Ellis MJ. Washington University School of Medicine, St Louis, MO; The Genome Institute at Washington University, St Louis, MO; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC.
- 10:45 am S3-06. Emergence of constitutively active estrogen receptor mutations in advanced estrogen receptor positive breast cancer**
Jeselsohn RM, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Cristofanilli M, Arteaga CL, Balko J, Gilmore L, Schnitt S, Come SE, Pusztai L, Stephens P, Miller VA, Brown M. Dana Farber Cancer Institute, Boston, MA; Foundation Medicine, Cambridge, MA; MD Anderson, Houston, TX; Thomas Jefferson University, Philadelphia, PA; Vanderbilt University, Nashville, TN; Beth Israel Deaconess Medical Center, Boston, MA; Yale University, New Haven, CT.

- 11:00 am S3-07. Letrozole plus dasatinib improves progression-free survival (PFS) in hormone receptor-positive, HER2-negative postmenopausal metastatic breast cancer (MBC) patients receiving first-line aromatase inhibitor (AI) therapy**
Paul D, Vukelja SJ, Holmes FA, Blum J, McIntyre KJ, Kumar AR, Lindquist DL, Osborne CR, Sanchez IJ, Goldschmidt JH, Wang Y, Asmar L, Lee ME, Wu N, Logie K, O'Shaughnessy J. US Oncology Research, McKesson Specialty Health, The Woodlands, TX; Rocky Mountain Cancer Center, Denver, CO; Texas Oncology - Tyler, Tyler, TX; Texas Oncology - Houston Memorial City, Houston, TX; Texas Oncology-Baylor Sammons Cancer Center, Dallas, TX; Texas Oncology - Dallas Presbyterian Hospital, Dallas, TX; Arizona Oncology Associates, Sedona, AZ; Texas Oncology - El Paso West, El Paso, TX; Blue Ridge Cancer Care - Christiansburg Office, Christiansburg, VA; Virginia Oncology Associates, Norfolk, VA; New York Oncology Hematology - Albany Medical Center, Albany, NY; Central Indiana Cancer Centers, Fishers, IN.

11:15 am S3-08. Discussant (S3-05 to S3-07)

11:30 am–12:00 pm

AACR DISTINGUISHED LECTURESHIP IN BREAST CANCER RESEARCH – Exhibit Hall D

Signatures of Mutational Processes in Human Cancer

Michael Stratton, FMedSci FRS
The Wellcome Trust Sanger Institute
Cambridge, UNITED KINGDOM

12:00 pm–1:00 pm

LUNCH AND EXHIBITS

1:00 pm–2:00 pm

CASE DISCUSSION 1 – Ballroom A

1:00 pm–2:00 pm

BASIC SCIENCE FORUM – Ballroom B

Cancer Metabolism

Moderator: Carlos L. Arteaga, MD
Vanderbilt-Ingram Cancer Center
Nashville, TN

1:00 pm

Hypoxic metabolism in breast cancer - how to overcome resistance to anti-angiogenic therapy

Adrian L. Harris, BSc, DPhil
Oxford University
Oxford, UNITED KINGDOM

1:30 pm

Alterations in tumor metabolism to support breast tumor growth and progression

Matthew Vander Heiden, MD, PhD
Massachusetts Institute of Technology
Cambridge, MA

2:15 pm–3:15 pm

MINI-SYMPOSIUM 1 – Exhibit Hall D

Adoptive T-cell Treatment

Moderator: Malcolm K. Brenner, MD, PhD
Baylor College of Medicine
Houston, TX

2:15 pm

T-Cell receptor gene therapy for the treatment of cancer

Richard A. Morgan, PhD
National Cancer Institute
Bethesda, MD

2:45 pm

Artificial receptors and the cellular therapy of cancer

Malcolm K. Brenner, MD, PhD
Baylor College of Medicine
Houston, TX

3:15 pm–5:00 pm

GENERAL SESSION 4 – Exhibit Hall D

- 3:15 pm S4-01. An integrated genomics approach identifies novel drivers of oncogenic pathway activity in human breast cancer**
Gatza ML, Silva G, Hoadley KA, Fan C, Perou CM. University of North Carolina at Chapel Hill, Chapel Hill, NC.
- 3:30 pm S4-02. Integrated genomic analyses of members of protein kinase C family identifies subtype specific alterations as novel therapeutic targets**
Natrajan RC, Leonidou A, Brough R, Frankum J, Wai PT, Ng CK, Reis-Filho JS, Lord CJ, Ashworth A. The Institute of Cancer Research, London, United Kingdom; Memorial Sloan-Kettering Cancer Center, New York, NY.
- 3:45 pm S4-03. Exome sequencing reveals clinically actionable mutations in the pathogenesis and metastasis of triple negative breast cancer**
Blackwell KL, Hamilton EP, Marcom PK, Peppercorn J, Spector N, Kimmick G, Hopkins J, Favaro J, Rocha G, Parks M, Love C, Scotland P, Dave SS. Duke Cancer Institute, Durham, NC; Forsyth Oncology, Winston-Salem, NC; Novant Oncology Research, Charlotte, NC.
- 4:00 pm S4-04. Overcoming resistance to PI3K inhibitors in PIK3CA mutant breast cancer using CDK4/6 inhibition: Results from a combinatorial drug screen**
Vora SR, Kim N, Costa C, Lockerman EL, Li X, Chen Y, Cao A, Pinzon-Ortiz M, Liu M, Kim S, Schlegel R, Huang A, Engelman JA. Massachusetts General Hospital, Boston, MA; Novartis Institutes for BioMedical Research, Cambridge, MA.
- 4:15 pm S4-05. Exome sequencing identifies shift in TP53 and PIK3CA mutation status after paclitaxel-based neoadjuvant chemotherapy in breast cancer**
Jiang Y, Yu K-D, Shao Z-M. Shanghai Cancer Center, Fudan University, Shanghai, China.
- 4:30 pm S4-06. PIK3CA mutation predicts resistance to anti-HER2/chemotherapy in primary HER2-positive/hormone-receptor-positive breast cancer – Prospective analysis of 737 participants of the GeparSixto and GeparQuinto studies**
Loibl S, Denkert C, Schneeweis A, Paepke S, Lehmann A, Rezai M, Zahm D-M, Sinn P, Khandan F, Eidtmann H, Dohnal K, Huober J, Loi S, Pfitzner B, Fasching PA, Andre F, Lindner J, Sotiriou C, Guo S, Gade S, Nekljudova V, Untch M, von Minckwitz G. Germa Breast Group, Neu-Isenburg; Charite, Berlin; National Center for Tumor Diseases, Heidelberg; Klinikum rechts der Isar der TU, München; Luisenkrankenhaus Düsseldorf, Düsseldorf; SRH Wald-Klinikum, Gera; Agaplesion Markus Krankenhaus, Frankfurt; Universitätsklinikum Schleswig-Holstein, Kiel; Zentrum für Pathologie & Zytologie, Düsseldorf; Universitätsklinikum, Ulm; Peter MacCallum Cancer Centre, Melbourne; Universitätsklinikum, Erlangen; Institut Gustave Roussy, Villejuif; Institut Jules Bordet, Brussels; Helios Kliniken, Berlin; Frauenklinik Frankfurt.
- 4:45 pm S4-07. TBA**

5:00 pm–7:00 pm

POSTER DISCUSSION 3 ENDOCRINE RESISTANCE – Ballroom A

5:00 pm–7:00 pm

POSTER DISCUSSION 4 MOLECULAR TUMOR BOARD – Ballroom B

5:00 pm–7:00 pm

POSTER SESSION 3 & reception – Exhibit Halls A–B**Tumor Cell and Molecular Biology**

- P3-01 Metabolism and Breast Cancer
P3-02 Cell Cycle Regulation
P3-03 Cellular Mechanisms
P3-04 DNA Damage and Repair

Prognosis and Response Prediction

- P3-05 Biomarkers – Methods

Epidemiology, Risk, and Prevention

- P3-06 Epidemiology – Population
P3-07 Epidemiology – Genetic and Molecular

Psychosocial, Quality of Life, and Educational Aspects

- P3-08 Survivorship Research
P3-09 Quality of Life – Supportive Care
P3-10 Palliation and Support – Pain Management
P3-11 Psychosocial Aspects

Treatment

- P3-12 Adjuvant Chemotherapy
P3-13 Advanced Chemotherapy
P3-14 Neoadjuvant Chemotherapy
P3-15 Toxicities Management

Ongoing Clinical Trials 2

- OT2-1 Radiation Therapy
OT2-2 Surgery
OT2-3 DCIS
OT2-4 Case Management
OT2-5 Survivorship
OT2-6 Targeted Therapies

7:30 pm–10:30 pm

OPEN SATELLITE EVENT – presented by Letters and Sciences – Marriott Rivercenter**BRCA Mutations: Strategies for Reducing Risk & Emerging Therapies**

7:30 pm–10:30 pm

OPEN SATELLITE EVENT – presented by Carden Jennings Publishing Co., Ltd. – Marriott Rivercenter**Interactive Updates in Women's Cancers: Focus on the Management of Skeletal-Related Events in Breast Cancer**

7:30 pm–10:00 pm

OPEN SATELLITE EVENT – presented by Clinical Care Options, LLC – Marriott Rivercenter**Bone-Targeted Agents for Breast Cancer: A Team Quiz Game**

FRIDAY, DECEMBER 13, 2013

7:00 am–5:15 pm

REGISTRATION – Bridge Hall

7:30 am–9:00 am

POSTER SESSION 4 & continental breakfast – Exhibit Halls A–B

Detection and Diagnosis

- P4-01 Molecular, Functional, and Novel Imaging
- P4-02 Radiology / Tumor Monitoring
- P4-03 Detection and Diagnosis – Other

Tumor Cell and Molecular Biology

- P4-04 Genomics
- P4-05 Molecular Profiles
- P4-06 Tumor Heterogeneity / Molecular Subclassification
- P4-07 Micro RNAs

Epidemiology, Risk, and Prevention

- P4-08 Prevention – Behavioral Interventions
- P4-09 Prevention – Nutritional Studies
- P4-10 Prevention – Clinical Trials
- P4-11 Prevention – Preclinical Studies

Treatment

- P4-12 HER2-Targeted Therapy
- P4-13 Immunotherapy (Clinical)
- P4-14 Antiangiogenic Therapy
- P4-15 Novel Targets and Agents
- P4-16 New Drugs and Treatment Strategies
- P4-17 Clinical Trials Design and Management
- P4-18 Research Resources – Patients
- P4-19 Research Resources – Tissue and Data Banks

9:00 am–9:30 am

PLENARY LECTURE 3 – Exhibit Hall D

Psychosocial/Survivorship Issues: Are we doing better?

Lesley Fallowfield, BSc, DPhil
University of Sussex
Falmer, UNITED KINGDOM

9:30 am–11:30 am

GENERAL SESSION 5 – Exhibit Hall D

9:30 am S5-01. Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance)
Sikov WM, Berry DA, Perou CM, Singh B, Cirincione C, Tolaney S, Kuzma CS, Pluard TJ, Somlo G, Port E, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis C, Winer EP. Miriam Hospital and Alpert Medical School of Brown University, Providence, RI; University of Texas MD Anderson Cancer Center, Houston, TX; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC; New York University Medical Center, New York, NY; Alliance Statistical Center, Durham, NC; Dana Farber Cancer Institute, Boston, MA; Southeast Cancer Control Consortium, Winston-Salem, NC; Washington University-St. Louis Medical Center, St. Louis, MO; City of Hope Comprehensive Cancer Center, Duarte, CA; Mount Sinai Medical Center, New York, NY; Patient Advocates in Research, Danville, CA; University of Chicago Medical Center, Chicago, IL; Memorial Sloan-Kettering Cancer Center, New York, NY.

9:45 am S5-02. Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY 2 TRIAL

Rugo HS, Olopade O, DeMichele A, van 't Veer L, Buxton M, Hylton N, Yee D, Chien AJ, Wallace A, Site PI's, Lyandres J, Davis S, Sanil A, Berry D, Esserman L. University of California San Francisco Helen Diller Family Comprehensive Cancer Center; University of Chicago; University of Pennsylvania; University of Minnesota; University of Texas MD Anderson Cancer Center; I-SPY 2 Clinical Trial Sites; University of California San Diego; Berry Consultants, LLC.

10:00 am S5-03. Discussant (S5-01 to S5-02)

10:15 am S5-04. Primary results of ROSE/TRIO-12, a randomized placebo controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer
Mackey JR, Ramos-Vazquez M, Lipatov O, McCarthy N, Kraznozhon D, Semiglazov V, Manikhas A, Gelmon K, Konecny G, Webster M, Hegg R, Verma S, Gorbounova V, Abi Gerges D, Thireau F, Fung H, Simms L, Buysse M, Ibrahim A, Martin M. Cross Center Institute, Edmonton, Canada; Centro Oncologico de Galicia "José Antonio Quiroga y Pineiro", A Coruña, Spain; Republican Clinical Oncology Dispensary of Ministry of Health of Bashkortostan Republic, Ufa, Russian Federation; Haematology and Oncology Clinic Australia Wesley Medical Center, Queensland, Australia; Leningrad Regional Oncology Dispensary, Leningrad, Russian Federation; Institute of Oncology N.N. Petrov, St. Petersburg, Russian Federation; City Clinical Oncology Dispensary, St. Petersburg, Russian Federation; British Columbia Cancer Agency, Vancouver, Canada; University of California, Los Angeles, CA; Tom Baker Cancer Centre, Calgary, Canada; Hospital Pérola Bygton Centro de Referência da Saúde da Mulher, Sao Paulo, Brazil; Sunnybrook Health Sciences Center, Toronto, Canada; N.N. Blokhin Russian Cancer Research Center of Russian Academy of Medical Sciences, Moscow, Russian Federation; Middle East Institute of Health, Bsalim, Lebanon; Translational Research in Oncology, Edmonton, Canada; ImClone Systems LLC, a wholly owned subsidiary of Eli Lilly and Co., Bridgewater, International Drug Development Institute (IDDI), Louvain-la-Neuve, Belgium; Hospital General Universitario Gregorio Marañón, Madrid, Spain.

10:30 am S5-05. Postneoadjuvant treatment with zoledronate in patients with tumor residuals after anthracyclines-taxane-based chemotherapy for primary breast cancer – The phase III NATAN study (GBG 36/ABCSG XX)

von Minckwitz G, Rezaei M, Eidtmann H, Tesch H, Huober J, Gerber B, Zahn DM, Costa S, Gnant M, Blohmer JU, Denkert C, Hanusch C, Jackisch C, Kümmel S, Fasching PA, Schneeweiss A, Paepke S, Untch M, Nekljudova V, Mehta K, Loibl S. German Breast Group, Neu-Isenburg, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitäts-Frauenklinik Kiel, Germany; Onkologische Gemeinschaftspraxis, Frankfurt, Germany; Frauenklinik Ulm, Germany; Universitäts-Frauenklinik Rostock, Germany; SRH Wald Klinikum Gera, Germany; Universitätsklinikum Magdeburg, Germany; Medical University of Vienna, Austria; Sankt Gertrauden Krankenhaus, Berlin, Germany; Charité University, Berlin, Germany; Rotkreuzklinikum München, Germany; Klinikum Offenbach, Germany; Kliniken Essen Mitte, Germany; University Erlangen, Germany; University Heidelberg; Klinikum Rechts der Isar der TU München, Germany; Helios Kliniken Berlin, Germany; Frauenklinik Frankfurt, Germany.

10:45 am S5-06. Epirubicin and cyclophosphamide (EC) followed by paclitaxel (T) versus fluorouracil, epirubicin and cyclophosphamide (FEC) followed by T, all given every 3 weeks or 2 weeks, in node-positive early breast cancer (BC) patients (pts). Final results of the Gruppo Italiano Mammella (GIM)-2 randomized phase III study

Cognetti F, Bruzzi P, De Placido S, De Laurentis M, Boni C, Aitini E, Durando A, Turletti A, Valle E, Garrone O, Puglisi F, Montemurro F, Barni S, Di Blasio B, Gamucci T, Colantuoni G, Olmeo N, Tondini C, Parisi AM, Bighin C, Pastorino S, Lambertini M, Del Mastro L. I.F.O. Istituto Regina Elena e Istituto San Gallicano - Mostacciano, Roma, Italy; IRCCS AOU San Martino-IST, Genova, Italy; Università degli Studi di Napoli Federico II, Napoli, Italy; Istituto Nazionale Tumori - IRCCS Fondazione Pascale, Napoli, Italy; Arcispedale S. Maria Nuova-IRCCS, Reggio Emilia, Italy; Ospedale di Mantova, Mantova, Italy; Città della Salute e della Scienza - ASO OIRM S Anna, Torino, Italy; Ospedale Evangelico Valdese - ASLTO1, Torino, Italy; Ospedale Businco, Cagliari, Italy; Oncologia ASO S. Croce e Carle, Cuneo, Italy; Azienda Ospedaliero Universitaria - Santa Maria della Misericordia, Udine, Italy; IRCCS Candiolo, Candiolo (Torino), Italy; Azienda Ospedaliera Treviglio, Treviglio (Bergamo), Italy; Azienda Ospedaliero-Universitaria di Parma, Parma, Italy; Unità Operativa Complessa di Oncologia della ASL di Frosinone, Frosinone, Italy; A.O.R.N. "S.G. Moscati", Avellino, Italy; UOC Oncologia Medica Ospedale Civile, Sassari, Italy; Ospedale Papa Giovanni XXIII, Bergamo, Italy; Ospedale S. Camillo-Forlanini, Roma, Italy.

11:00 am S5-07. SWOG S0500 – A randomized phase III trial to test the strategy of changing therapy versus maintaining therapy for metastatic breast cancer patients who have elevated circulating tumor cell (CTC) levels at first follow-up assessment

Smerage JB, Barlow WE, Hayes DF, Winer EP, Leyland-Jones B, Srkalovic G, Tejwani S, Schott AF, O'Rourke MA, Lew DL, Gralow JR, Livingston RB, Hortobagyi GN. University of Michigan, Ann Arbor, MI; MD Anderson Cancer Center, Houston, TX; Dana-Farber Cancer Institute, Boston, MA; Sanford Cancer Center, Sioux Falls, SD; Sparrow Health System, Lansing, MI; Greenville Health System Cancer Institute, Greenville, SC; Henry Ford Hospital, Detroit, MI; University of Arizona Cancer Center, Tucson, AZ; University of Washington - Seattle Cancer Care Alliance, Seattle, WA; SWOG Statistical Center, Seattle, WA.

11:15 am S5-08. Breast cancer incidence after hormonal infertility treatments: Systematic review and meta-analysis of population based studies

Gennari A, Costa M, Paleari L, Puntoni M, Sormani M, Decensi A, Bruzzi P. Galliera Hospital, Genoa, Italy; Evangelico Hospital, Genoa, Italy; AOU San Martino-IST, Genoa, Italy; University of Genoa, Genoa, Italy.

11:30 am–12:00 pm

AACR OUTSTANDING INVESTIGATOR AWARD FOR BREAST CANCER RESEARCH, funded by Susan G. Komen for the Cure® – Exhibit Hall D

TBA

12:00 pm–1:00 pm

LUNCH AND EXHIBITS

1:00 pm–2:00 pm

CASE DISCUSSION 2 – Ballroom A

1:00 pm–2:00 pm

BASIC SCIENCE FORUM – Ballroom B

New Frontiers in Migration and Metastasis - Exosome

Moderator: Xiang Zhang, PhD
Baylor College of Medicine
Houston, TX

1:00 pm

Tumor-derived exosomes promote pre-metastatic niche formation and organotropism

David C. Lyden, MD, PhD
Weill Cornell Medical College
New York, NY

1:30 pm

Planar cell polarity and the exosome in breast cancer metastasis

Jeffrey Wrana, PhD
Mount Sinai Hospital
Toronto, CANADA

2:15 pm–3:15 pm

MINI-SYMPOSIUM 2 – Exhibit Hall D

HER2+ Breast Cancer: Unresolved Challenges

Moderator: C. Kent Osborne, MD
Baylor College of Medicine
Houston, TX

2:15 pm

Translational insights in HER2+ breast cancer

Carlos L. Arteaga, MD
Vanderbilt-Ingram Cancer Center
Nashville, TN

2:45 pm

Clinical advances and challenges in the management of HER2+ breast cancer

Eric P. Winer, MD
Dana-Farber Cancer Institute
Boston, MA

3:15 pm–5:00 pm

GENERAL SESSION 6 – Exhibit Hall D

3:15 pm S6-01. JAK2 amplifications are enriched in triple negative breast cancers (TNBCs) after neoadjuvant chemotherapy and predict poor prognosis

Balko JM, Giltmane JM, Schwarz LJ, Sanders ME, Wang K, Harris LN, Lin NU, Miller VA, Stephens PJ, Yelensky R, Pinto JA, Gomez H, Arteaga CL. Vanderbilt University, Nashville, TN; Foundation Medicine, Cambridge, MA; Case Western Reserve University, Cleveland, OH; Dana Farber Cancer Institute, Boston, MA; Oncosalud, Lima, Peru; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.

3:30 pm

S6-02. Long-term prognostic value of residual cancer burden (RCB) classification following neoadjuvant chemotherapy

Symmans WF, Wei C, Gould R, Zhang Y, Hunt KK, Buchholz TA, Valero V, Hortobagyi GN, Pusztai L, Hatzis C. UT MD Anderson Cancer Center, Houston, TX; Yale Cancer Center, New Haven, CT.

3:45 pm S6-03. The prognosis of small HER2+ breast cancers: A meta-analysis of the randomized trastuzumab trials
 O'Sullivan CC, Holmes E, Spielmann M, Perez EA, Joensuu H, Costantino JP, Delaloge S, Rastogi P, Zardavas D, Ballman KV, de Azambuja E, Piccart-Gebhart M, Zujewski JA, Gelber RD. National Cancer Institute, National Institutes of Health, Bethesda, MD; Frontier Science Scotland, Kincaig, Inverness-shire, United Kingdom; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Brussels, Belgium; Mayo Clinic, Jacksonville, FL; University of Pittsburgh, Pittsburgh, PA; Helsinki University Central Hospital, Haartmaninkatu 4, Finland; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MI.

4:00 pm S6-04. Prediction of late distant recurrence after 5 years of endocrine treatment: A combined analysis of 2485 patients from the ABCSG-8 and transATAC studies using the PAM50 risk of recurrence (ROR) score
 Sestak I, Cuzick J, Dowsett M, Filipits M, Dubsy P, Cowens W, Ferree S, Schaper C, Fesl C, Gnant M. Centre for Cancer Prevention, Queen Mary University, London, United Kingdom; Royal Marsden Hospital, London, United Kingdom; Medical University of Vienna, Vienna, Austria; Nanostring Technologies, Seattle, WA; Myraqa, Redwood City, CA; Austrian Breast & Colorectal Cancer Study Group, Vienna, Austria.

4:15 pm S6-05. High levels of APOBEC3B, a DNA deaminase and an enzymatic source of C-to-T transitions, are a validated marker of poor outcome in estrogen receptor-positive breast cancer
 Sieuwerts AM, Burns M, Look MP, Meijer-Van Gelder ME, Schlicker A, Heidemann MR, Jacobs H, Wessels L, Willis S, Leyland-Jones B, Gray K, Foekens JA, Harris RS, Martens JW. Erasmus MC Cancer Institute, Cancer Genomics Netherlands, Erasmus University Medical Centre, Rotterdam, Netherlands; University of Minnesota, Minneapolis, MN; The Netherlands Cancer Institute, Amsterdam, Netherlands; Sanford Health and Research, Sioux Falls, SD; Dana-Farber Cancer Institute, Boston, MA.

4:30 pm S6-06. TBA

4:45 pm S6-07. TBA

5:00 pm–7:00 pm
POSTER DISCUSSION 5 Novel Targets and Agents – Ballroom A

5:00 pm–7:00 pm
POSTER DISCUSSION 6 Circulating Tumor Cells – Ballroom B

5:00 pm–7:00 pm
POSTER SESSION 5 & reception – Exhibit Halls A–B

Tumor Cell and Molecular Biology

- P5-01 Immunology and Preclinical Immunotherapy
- P5-02 Gene Therapy
- P5-03 Stem/Progenitor Cells
- P5-04 Progression, Invasion, and Metastasis
- P5-05 Hormonal Factors and Receptors
- P5-06 Growth Factors
- P5-07 Oncogenes and Tumor Suppressor Genes
- P5-08 Drug Resistance
- P5-09 Endocrine Therapy and Resistance
- P5-10 Systems Biology
- P5-11 Tumor Biology – Other

Epidemiology, Risk, and Prevention

- P5-12 Ethnic/Racial Aspects
- P5-13 Epidemiology, Risk, and Prevention – Other

Treatment

- P5-14 Radiation Therapy
- P5-15 Breast Conservation
- P5-16 DCIS / LCIS
- P5-17 Treatment – Other

Ongoing Clinical Trials 3

- OT3-1 Chemotherapy
- OT3-2 Endocrine Therapy
- OT3-3 Prevention

SATURDAY, DECEMBER 14, 2013

7:00 am–9:00 am
REGISTRATION – Bridge Hall

7:30 am–9:00 am
POSTER SESSION 6 & continental breakfast – Exhibit Hall C

Tumor Cell and Molecular Biology

- P6-01 Angiogenesis
- P6-02 Apoptosis and Senescence
- P6-03 Etiology / Carcinogenesis
- P6-04 Novel/Emerging Targets
- P6-05 Biomarkers

Prognosis and Response Prediction

- P6-06 Prognostic and Predictive Factors – General

Psychosocial, Quality of Life, and Educational Aspects

- P6-07 Cost Effectiveness
- P6-08 Social and QOL Aspects – Other

Treatment

- P6-09 Adjuvant Therapy – Other
- P6-10 Advanced Therapy – Other
- P6-11 Brain Metastases
- P6-12 Inflammatory Breast Cancer

9:00 am–11:00 am
THE YEAR IN REVIEW – Exhibit Hall D

Moderator: C. Kent Osborne, MD
 Baylor College of Medicine
 Houston, TX

9:00 am
Basic Research

Lewis A. Chodosh, MD, PhD
 University of Pennsylvania
 Philadelphia, PA

9:30 am
Translational research highlights for 2013

Charles M. Perou, PhD
 University of North Carolina at Chapel Hill
 Chapel Hill, NC

10:00 am
Clinical early breast cancer

Joseph A. Sparano, MD
 Montefiore Medical Center-Weiler Division
 Bronx, NY

10:30 am
Clinical metastatic breast cancer

Stephen R D Johnston, MA, FRCP, PhD
 The Royal Marsden Hospital
 London, UNITED KINGDOM

11:00 am
ADJOURNMENT

PRODUCT THEATRES

Wednesday, December 11 12:15 presented by Genentech

Wednesday, December 11 2:00 presented by Pfizer

Thursday, December 12 12:15 presented by GE Healthcare (Clariant)

Friday, December 13 12:15 presented by Genentech



The First Annual San Antonio Breast Cancer Symposium

was held November 11, 1978 during Breast Cancer Awareness Week, and was part of an intensive 3-year outreach program of public and professional education designed to significantly reduce the death rate caused by breast cancer in San Antonio and surrounding counties. It was sponsored by Cancer Therapy and Research Center (CTRC) and the American Cancer Society, Texas Division, in conjunction with The University of Texas Health Science Center at San Antonio (UTHSCSA) and the Bexar County Medical Society. That all-day course for physicians and surgeons was organized and co-directed by Charles A. Coltman, Jr., MD, and William L. McGuire, MD, both Professors of Medicine at UTHSCSA. It featured invited presentations by a panel of internationally known specialists and was attended by 141 physicians and surgeons from a 5-state area. Three years later, in 1981, the meeting was expanded to two days, a call for abstracts was distributed worldwide, and proffered papers for slide and poster presentations were incorporated into the program, thereby broadening its scope to both attract and draw from a larger, international base. Renowned experts gave formal plenary lectures, and accepted abstracts were published for the first time in the peer-reviewed journal *Breast Cancer Research and Treatment*. Case discussion lunches offered opportunity for discussion of complex clinical problems in the management of primary and metastatic disease, by a panel of physicians from different disciplines. Although some modifications have been made in the format, such as incorporating pre-symposium educational sessions, Year In Review, and lunchtime forums, the overall format remains very much the same. This reflects the objective of the Symposium, which is to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease, to an international audience of academic and private physicians and researchers.

In 1990, CTRC and UTHSCSA formally entered into a collaboration known as the San Antonio Cancer Institute (an NCI designated Comprehensive Cancer Center), which in 1995 assumed direct sponsorship of the Symposium. In 1992, C. Kent Osborne, MD became Co-Director of the symposium upon the death of William L. McGuire, MD. In 1999, Dr. Osborne left UTHSCSA and opened the Breast Center at Baylor College of Medicine, and in 2005, Baylor College of Medicine became a joint sponsor of the symposium.

In 2008 the American Association for Cancer Research became a joint sponsor of the symposium. Through the efforts of UTHSCSA, AACR, and BCM, the program attracts more thought-leaders and high-quality proffered papers in basic and translational breast cancer research as well as increasing the participation of young investigators by providing superior education and training opportunities for the next generation of breast cancer researchers.

The driving force behind the collaboration is the shared mission of the partners to advance progress against breast cancer. By combining their respective strengths, the partnership will produce a scientific meeting that encompasses the full spectrum of breast cancer research, facilitating the rapid translation of new knowledge into better care for breast cancer patients.

In 2010 Peter M. Ravdin, MD, PhD, Ruth McLean Bowman Bowers Chair for Breast Cancer Research & Treatment, Director, Breast Cancer Program at the Cancer Therapy & Research Center at UT Health Science Center, assumed the role of Co-Director of the symposium upon the retirement of Charles A. Coltman, Jr, MD. Dr. Coltman remains Co-Director, ex-officio.

In 2011 Carlos L. Arteaga, Professor of Medicine and Cancer Biology, Interim Director, Division of Hematology-Oncology, Director, Breast Cancer Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University was appointed Co-Director of the symposium representing American Association for Cancer Research. The UT Health Science Center San Antonio School of Medicine, through the Office of Continuing Medical Education, continues to be the provider of CME sponsorship for this premier breast cancer symposium.

SYMPOSIUM OBJECTIVE

This symposium is designed to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease to an international audience of academic and private physicians and researchers.

STRUCTURE

The scientific program consists of formal lectures by experts in clinical and basic research, selected slide and poster presentations, forums and case discussions. The official language of the symposium is English. Simultaneous translation is not provided.

ACCREDITATION

The UT Health Science Center San Antonio School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The UT Health Science Center San Antonio School of Medicine designates this live activity for a maximum of 41.50 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses and other healthcare professionals will receive a Certificate of Attendance. For information on applicability and acceptance, please consult your professional licensing board.

FINANCIAL DISCLOSURE STATEMENT

As an ACCME-accredited CME provider, the UT Health Science Center at San Antonio School of Medicine (UTHSCSA SOM) must ensure that its CME activities are independent of the control of commercial interests. All speakers and planning committee members for UTHSCSA sponsored programs are expected to disclose (prior to the activity) all "relevant financial relationships" as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. ("Relevant" financial interest or other relationships can include such things as grant or research support, employees, consultants, major stockholders, members of speaker bureau, etc.)

The UTHSCSA CME Office and Peter M. Ravdin, course director and content reviewer for the 2013 San Antonio Breast Cancer Symposium, has reviewed all financial disclosure information for all speakers, facilitators, and planning committee members; and determined and resolved all conflicts of interests.

Disclosure information will be posted on the Symposium website www.sabcs.org in November.

BADGES REQUIRED

Past and current events have heightened security awareness around the world. Although no one can predict world events, incidents or situations, we are working to help ensure a safe and successful Symposium. To this end, we will require attendees to wear the Symposium Name Badge to ALL Symposium activities (sessions, exhibits, etc.) at the convention center.

Thank you for your cooperation.

LOCATION

The symposium takes place at:

Henry B. Gonzalez Convention Center
200 E. Market St.
San Antonio, TX 78205

The main entrance to the symposium is located on street level across Market St. from the Marriott Riverwalk.

Symposium events & services are located on two levels of the convention center.

Street (1st) level (Bridge Hall, Exhibit Halls A, B, C & D, Ballrooms A & B)

Entrance

Coat check, baggage check, scooter rental, First Aid station

Bridge Hall

Registration, Housing, Information & Message Center, Poster pickup, Information/Job boards, Boarding Pass Printing, Internet Cafe

Exhibit Halls A & B

Poster Sessions (Wednesday–Friday), Poster QR Code boards, Continental Breakfast (Thursday–Friday), Receptions (Wednesday–Friday), Food Court

Exhibit Hall C

Exhibits, Product Theatre, Poster Session (Saturday), Loading dock (for exhibitors), Lounge, First Aid station, Dining: Continental breakfast (Wednesday and Saturday), concessions

Exhibit Hall D

Educational Sessions, General Sessions, Award Lectures, Mini-Symposia, Plenary Lectures

Ballroom A

Educational Sessions, Clinical Science Forum, Case Discussions, Poster Discussions

Ballroom B

Educational Sessions, Basic Science Forums, Poster Discussions

Concourse (2nd) level

Park View Atrium

Press Room, Speaker lounge

Room 214

Career Development Forum

SMOKE-FREE ENVIRONMENT

The Henry B. Gonzalez Convention Center is a non-smoking facility. No smoking is allowed anywhere in the building.

CLIMATE & COMFORT

The average temperature in San Antonio in December ranges from 45°F to 65°F (7°C to 18°C). Remember that meeting rooms are usually kept quite cool, so dress accordingly. For such a large audience, it is necessary to maintain a lower temperature than is comfortable for everyone.

FOOD & BEVERAGES

Continental breakfast, evening poster session receptions & beverages are provided free of charge.

Lunch tickets for 2013 SABCS are offered for either

1. \$14.00 Boxed lunch and a soda or water; redeemable at the Express Lunch area located in Exhibit Hall C.
2. \$18.00 A hot item, soda or water and a dessert; redeemable at the Food Court located in Exhibit Hall B.

No refund or partial refund will be issued for a Ticket or for a partial redemption of a Ticket.

Tickets can be purchased in advance for individuals & groups.

SYMPOSIUM INFORMATION

EXHIBIT HOURS

Wednesday, December 11, 2013	11:00 AM–5:00 PM
Thursday, December 12, 2013	11:00 AM–5:00 PM
Friday, December 13, 2013	11:00 AM–5:00 PM

Exhibits will be featured in Exhibit Hall C.

FOR CURRENT INFORMATION, ON-LINE REGISTRATION AND HOUSING PLEASE REFER TO OUR WEBSITE

<http://www.sabcs.org>

REGISTRATION HIGHLIGHTS

- Everyone must register.
- Discounted rates are available through October 31.
- You may register online at www.sabcs.org or download and print out a registration form in PDF format, until November 15. After that date, you must register on site in Bridge Hall at the Henry B. Gonzalez Convention Center.
- If your pre-registration is postmarked or faxed after the cutoff date, it will not be processed and you must register on site.
- SABCS has unlimited attendance and preregistration is not required.
- Registration will be CLOSED from November 16 through December 9.
- Registration will resume on site at 8:00 AM on December 10.
- All payments must be in US currency, and payment must accompany registration.
- Symposium badges will be mailed to pre-registrants prior to the symposium.
- All participants receive their symposium materials and badge holders at SABCS registration.

Registration Category Until October 31 / After October 31

Regular Registration.....	\$450 / \$600
Regular Registration: AACR members with member ID.....	\$382.50 / \$510
Regular Registration: UTHSCSA & BCM staff & faculty With valid ID.....	\$200 / \$275
MD Resident or Postdoctoral fellow With valid ID or letter of appointment.....	\$100 / \$120
PhD Postdoctoral fellow With valid ID or letter of appointment.....	\$100 / \$120
Medical Student With valid ID.....	\$0
PhD Student With valid ID.....	\$0
Patient Advocate Must provide name of valid patient advocate organization representing.....	\$100 / \$120
Press.....	\$0

SPECIAL ASSISTANCE

If you require special assistance, please contact the symposium office at 210-450-1550 or sabcs@uthscsa.edu.

EXHIBITOR REGISTRATION

All Exhibitors must check in at the Exhibitor registration counter. All exhibitors and staff must register. No one will be allowed on the floor without a badge.

Please refer to Support & Exhibits Information on the symposium website (www.sabcs.org) for information regarding registrations for exhibit staff. All other registrants will pay the regular registration fee, subject to the preregistration deadline of November 15.

Exhibitor Registration Hours

Monday, Dec 9	12:00 PM – 5:00 PM
Tuesday, Dec 10	8:00 AM – 7:00 PM
Wednesday, Dec 11	7:00 AM – 5:15 PM
Thursday, Dec 12	7:00 AM – 5:15 PM
Friday, Dec 13	7:00 AM – 5:00 PM

GROUP REGISTRATION

Information is available on the symposium website (www.sabcs.org), or refer to page 25 of this booklet. Group Registrations must be received by November 15.

PRESS REGISTRATION

The symposium provides complimentary registration to professional journalists representing media organizations for the express purpose of gathering news and information to produce editorial coverage of the meeting.

Valid credentials are required of every journalist and PIO in order to complete registration. These credentials include an official press identification (business card, press pass, etc) and two bylined articles (or a copy of the editorial masthead if articles are not bylined), or a letter of assignment. For further information visit our website at www.sabcs.org/Media/Index.asp. Please fax the media registration form on page 30 along with these valid credentials to Lauren Riley, American Association for Cancer Research, at 215-440-9319. For further information, please call 215-446-7155 or e-mail lauren.riley@aacr.org.

SPOUSE/GUEST REGISTRATION

Available on-site only. One spouse/guest registration can be included with each regular registration. Please note that spouse/guest registration includes access ONLY to exhibits, does not include symposium materials, and is not valid for CME credits.

ID REQUIRED FOR ONSITE BADGE PICK UP

For security purposes, all attendees picking up their badges onsite must present a photo ID in order to receive their badge. Please be sure to bring your photo ID with you to the Henry B. Gonzalez Convention Center.

On Site Registration Hours

Tuesday, Dec 10	8:00 AM – 7:00 PM
Wednesday, Dec 11	7:00 AM – 5:15 PM
Thursday, Dec 12	7:00 AM – 5:15 PM
Friday, Dec 13	7:00 AM – 5:15 PM
Saturday, Dec 14	7:00 AM – 9:00 AM

ON-SITE CHECK-IN

SABCS encourages all attendees to take advantage of early On Site Registration on Tuesday, December 10, 8:00 am – 7:00 pm. All registration counters will be open.

Registration will be located in Bridge Hall at the Henry B. Gonzalez Convention Center.

All those who registered before the deadline and have their badge, should proceed to the Pre-Registered counters in Bridge Hall to receive meeting materials and a badge holder. Badges are required in order to pick up meeting materials.

Individuals who missed the pre-registration deadline must register on site at the On-Site Registration counters in Bridge Hall.

CANCELLATIONS AND REFUNDS

Please send written notice of cancellation by fax to 210-450-1560 or email sabcs@uthscsa.edu.

Cancellations received on or before November 15, 2013 will be refunded less the following processing fees: \$75.00 Regular Registration, \$20.00 Fellow, \$20.00 Patient Advocate. Cancellations received after November 15, 2013 are non-refundable. If canceling your registration will also result in cancellation of your slide or poster presentation, please so state when giving notice.

HOTEL ACCOMMODATIONS

The meeting site for the 2013 Symposium is the Henry B. Gonzalez Convention Center, 200 E. Market Street, located downtown on the scenic Riverwalk, and is within easy walking distance of many restaurants and stores.

The Marriott Rivercenter remains our headquarters hotel. Additional rooms at special SABCS rates have also been obtained at more than 26 other hotels nearby, and all requests will be processed by SABCS Housing Bureau. Information and online reservations for both groups and individuals are available on the SABCS website.

You may also refer to pages 19–22 of this book for information and forms for reservations by fax or mail.

TRANSPORTATION

Transportation From Airport To Hotel

GO Airport Shuttle, San Antonio Airport's official shuttle service, has shuttles departing to and from downtown approximately every 15 minutes from 7:00 AM–1:30 AM daily.

Shuttle tickets are sold at the baggage claim area. Ticket rates are \$19.00 per person to downtown hotels or \$34.00 for a roundtrip ticket. Book online and receive an additional discount. Online rates are \$17.00 to downtown hotels and \$32.00 for a roundtrip ticket. Major credit cards are accepted. For 24 hour reservations and information, call 210-281-9900, or go online to www.goairportshuttle.com.

Taxi fare is approximately \$27.00. As many as 4 people may ride for the price of 1. SABCS does not provide transportation from the airport to the meeting.

Symposium Shuttle Buses

SABCS provides free shuttle bus transportation between symposium hotels and the convention center December 10–14, 2013.

- Shuttle buses will travel frequently between symposium hotels and the convention center.
- This service is free.
- Buses will drop off and pick up at the Market Street Entrance of the Henry B. Gonzalez Convention Center.
- Buses will only stop at the official symposium hotels.

- A wheelchair accessible bus will be available during the listed days and times. It is necessary to make reservations for this service by calling Circa Texas at 210-394-0607. Please call 24 hours in advance to make your reservation at your specific hotel.
- For current schedule and any additional stops which may be added, please visit www.sabcs.org. Shuttle routes and times are available on the symposium website at www.sabcs.org.
- SABCS does not provide transportation from the airport to hotels.

CHILDREN

Due to liability restrictions and concerns, children under eighteen years of age may not participate in any part of this conference.

PHOTOGRAPHY

Still photography is allowed for personal use only. Publication of any photos is prohibited without the express permission of SABCS. In order to take photos for publication, journalists must be registered as press. See page 30 for information regarding press registration.

Video cameras are granted access to the Registration area and press room. Access to other areas of the Symposium requires pre-approval from SABCS. Still cameras are granted access to all areas of the Symposium. "Flash" photography is not allowed in order to minimize disturbance to attendees. Camera crews filming in meeting areas other than the press room or news briefing room must be accompanied at all times by a press room staff member.

Photographers or camera crews hired by the aforementioned representatives or exhibitors must obtain permission from press room staff to conduct any on-site photo or video shoots during the Symposium.

CELL PHONES

Ringing phones and conversations make it difficult for your colleagues to fully benefit from SABCS sessions. To provide an environment conducive to education, we ask that you observe the following courtesies while inside the symposium:

- Please turn your cellular phone off or switch to a silent mode.
- If receiving a call, please immediately put the call on hold and move to a foyer or similar area to use your phone.
- If making a call, we ask that you move to a foyer or similar area to initiate your call.

WI-FI

SABCS will offer wireless service throughout the symposium. Connection setting information and a support specialist will be available onsite.

INTERNET CAFÉ

SABCS will operate an Internet Café with approximately 15 computers for internet and e-mail access located in Bridge Hall.

LITERATURE DISPLAYS

Literature racks will be available for non-profit organizations only for posting of brochures, which must not exceed 8½x11 inches. Please contact the Symposium office at sabcs@uthscsa.edu for instructions.

SYMPOSIUM INFORMATION

INFORMATION BOARDS

Information boards will be located in Bridge Hall. Recruitment opportunities, meeting announcements, etc can be posted on these boards with the approval of the symposium office. Please contact the Symposium office at sabcs@uthscsa.edu for instructions.

SAN ANTONIO SIGHTS

Although SABCS does not sponsor any recreational activities, visitors to the city may obtain such information from the website of San Antonio Convention and Visitors Bureau (www.sanantoniocvb.com).

DINING IN SAN ANTONIO

Creative Dining & Entertainment staff will recommend and make your individual and/or group reservations at San Antonio's most enjoyable restaurants and/or catering venues! The staff can also help you arrange your rental car, golf tee time, other entertainment and relaxation needs. Their service is free, and is available now either by phone 210-618-5279, fax 210-468-0674 or e-mail skylar@creativedining.net or on their website www.creativedining.net. Staff will also be available onsite during the Symposium in West Registration during the following hours:

Tuesday, Dec. 10.....	11:30 AM – 7:30 PM
Wednesday, Dec. 11.....	11:00 AM – 8:00 PM
Thursday, Dec. 12.....	11:00 AM – 8:00 PM
Friday, Dec. 13.....	11:00 AM – 8:00 PM

IMPORTANT DATES

Advance Registration Discount Deadline.....	October 31, 2013
Advance Registration Deadline.....	November 15, 2013
Hotel Reservation Deadline.....	November 15, 2013
Registration Cancellation Deadline.....	November 15, 2013
Career Development Forum Registration Deadline.....	November 15, 2013
Onsite Registration Opens.....	December 10, 2013
Symposium Begins.....	December 10, 2013
Symposium Ends.....	December 14, 2013

SABCS ON-LINE

- Each SABCS attendee will receive a user name & password which will allow access to 2013 SABCS abstracts, posters, slides, and webcast of oral presentations online.
- **Abstracts Online:** searchable version of the SABCS abstracts, will be available to attendees during the symposium. Abstracts will be posted on the day of presentation. Check our website www.sabcs.org. These abstracts will also be published in the symposium's abstract book, a special supplement to the AACR journal *Cancer Research* which is available to each attendee online. Please note: There will not be a printed abstract book.
- **Slides Online:** will be available to view by attendees on the day of presentation. Select slides will be downloadable, author permitting.
- **Posters Online:** searchable version of the posters will be posted on line for attendees to view during the symposium, author permitting.
- **Webcast:** All oral presentations for which the authors have given permission will be posted approximately 2 days following the symposium.

- 2013 SABCS abstracts, posters, slides, and webcasts of oral presentations will be made available online to non-attendees January 1, 2014.
- At this time, SABCS plans to keep all of the above available on line for 3 years.

SABCS MOBILE APP

Receive symposium updates, information in the palm of your hand

Discover your smartphone's hidden potential and stay connected to the San Antonio Breast Cancer Symposium (SABCS) on the go with this free official symposium application, developed by Ascend Integrated Media.

- Download the app from iPhone app store, Android Play Station, or Google Store. Enter "SABCS 2013" into the Search field and install or go to the following web address in your phones browser: <http://crowd.cc/zy>
- To access the information on the app (a full listing of symposium sessions and speakers) as a Web page: Visit the mobile ready site at <http://crowd.cc/sabcs2013>

This app features symposium information including registration, housing, transportation, and preliminary schedule. The app will be continually updated as new information becomes available.

Coming Soon

- Program search and itinerary builder allows you to view events and sessions by date and category. You can create your own individual itinerary of sessions, which then may be exported to email calendar for printing.
- Mobile texting program to SABCS attendees (opt in).
- Online Exhibitor Guide
 - Search exhibitors via various criteria
 - Search results provides a map which shows exhibitor location
 - Create your own personalized list of exhibitors

NEWSLETTER

A daily newsletter featuring highlights of the symposium, late breaking & revised abstracts, schedule changes and other news is published during the symposium. It is distributed on site and posted at www.sabcs.org.

CONTACT INFORMATION

Rich Markow, Director, Symposia
Cancer Therapy & Research Center at UT Health Science Center
7979 Wurzbach Road, MC 8224
San Antonio, TX 78229 USA
E-mail: sabcs@uthscsa.edu
Phone: 210-450-1550 FAX: 210-450-1560
Symposium website: www.sabcs.org

EXECUTIVE COMMITTEE

Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN
 Gary C. Chamness, Baylor College of Medicine, Houston, TX
 Margaret Foti, American Association for Cancer Research, Philadelphia, PA
 Ismail Jatoi, UT Health Science Center, San Antonio, TX
 C. Kent Osborne, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX
 Peter M. Ravdin, UT Health Science Center, San Antonio, TX
 Andrea Richardson, Dana-Farber Cancer Institute, Boston, MA
 Rachel Schiff, Baylor College of Medicine, Houston, TX
 Ian M. Thompson, Jr., UT Health Science Center, San Antonio, TX

PROGRAM PLANNING COMMITTEE

Carlos L. Arteaga, AACR (Co-Chair), Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN
 Lisa A. Carey, University of North Carolina, Chapel Hill, NC
 Patricia Chalela, UT Health Science Center, San Antonio, TX
 Gary C. Chamness, Baylor College of Medicine, Houston, TX (ex-officio)
 Richard L. Crownover, UT Health Science Center, San Antonio, TX
 Nancy E. Davidson, University of Pittsburgh Cancer Institute, Pittsburgh, PA
 Margaret Foti, American Association for Cancer Research, Philadelphia, PA (ex-officio)
 Suzanne A.W. Fuqua, Baylor College of Medicine, Houston, TX
 James N. Ingle, Mayo Clinic College of Medicine, Rochester, MN
 Ismail Jatoi, UT Health Science Center, San Antonio, TX
 Michael T. Lewis, Baylor College of Medicine, Houston, TX
 Rong Li, UT Health Science Center, San Antonio, TX
 Yi Li, Baylor College of Medicine, Houston, TX
 C. Kent Osborne (Co-Chair), Baylor College of Medicine, Houston, TX
 Susan W. Rafté, Pink Ribbons Project, Houston, TX
 Peter M. Ravdin (Co-Chair), UT Health Science Center, San Antonio, TX
 Andrea Richardson, Dana-Farber Cancer Institute, Boston, MA
 Mothaffar Rimawi, Baylor College of Medicine, Houston, TX
 Nicholas J. Robert, Virginia Cancer Specialists, Fairfax, VA
 Jeffrey M. Rosen, Baylor College of Medicine, Houston, TX
 Rachel Schiff, Baylor College of Medicine, Houston, TX
 Sandi Stanford, Alamo Breast Cancer Foundation, San Antonio, TX
 Nicholas Turner, Royal Marsden Hospital, London, UNITED KINGDOM
 Laura J. van 't Veer, University of California, San Francisco, CA
 Thomas Westbrook, Baylor College of Medicine, Houston, TX
 Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA
 Douglas Yee, University of Minnesota, Minneapolis, MN


ABSTRACT REVIEW COMMITTEE

Fabrice André, Institut Gustave Roussy, Villejuif, FRANCE
 Jose Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY
 Jonas Bergh, Karolinska Institutet, Stockholm, SWEDEN
 Melissa Bondy, Baylor College of Medicine, Houston, TX
 Angela Brodie, University of Maryland, Baltimore, MD
 Powel H. Brown, UT MD Anderson Cancer Center, Houston, TX
 Rowan Chlebowski, Los Angeles BioMed Research Institute at Harbor-UCLA Medical Center, Torrance, CA
 Robert Coleman, Weston Park Hospital, Sheffield, UNITED KINGDOM
 Richard L. Crownover, UT Health Science Center, San Antonio, TX
 Angelo Di Leo, Hospital of Prato, Prato, ITALY
 Matthew Ellis, Washington University, Saint Louis, MO
 Heide L. Ford, University of Colorado School of Medicine, Aurora, CO
 Suzanne A.W. Fuqua, Baylor College of Medicine, Houston, TX
 Patricia A. Ganz, University of California, Los Angeles, CA
 Stefan Gluck, University of Miami, Miami, FL
 Michael Grant, Medical University of Vienna, Vienna, AUSTRIA
 Matthew P. Goetz, Mayo Clinic College of Medicine, Rochester, MN
 Ana Maria Gonzalez-Angulo, UT MD Anderson Cancer Center, Houston, TX
 Pamela J. Goodwin, Mount Sinai Hospital, Toronto, CANADA
 Cary P. Gross, Yale University School of Medicine, New Haven, CT
 M. Carolina Gutierrez, Baylor College of Medicine, Houston, TX

Jay R. Harris, Dana-Farber Cancer Institute, Boston, MA
 Lyndsay Harris, University Hospitals Medical Group, Cleveland, OH
 Daniel F. Hayes, University of Michigan Cancer Comprehensive Center, Ann Arbor, MI
 Dawn L. Hershman, Columbia University, New York, NY
 Susan G. Hilsenbeck, Baylor College of Medicine, Houston, TX
 Clifford A. Hudis, Memorial Sloan-Kettering Cancer Center, New York, NY
 Kelly Hunt, UT MD Anderson Cancer Center, Houston, TX
 Eun Sil Shelley Hwang, Duke University Medical Center, Durham, NC
 Steven Isakoff, Massachusetts General Hospital, Boston, MA
 Ismail Jatoi, UT Health Science Center, San Antonio, TX
 Heikki Joensuu, University of Helsinki, Helsinki, FINLAND
 Stephen RD Johnston, The Royal Marsden Hospital, London, UNITED KINGDOM

Yibin Kang, Princeton University, Princeton, NJ
 Seema Khan, Northwestern University, Chicago, IL
 Adrian V. Lee, University of Pittsburgh Cancer Institute, Pittsburgh, PA
 Michael T. Lewis, Baylor College of Medicine, Houston, TX
 Rong Li, UT Health Science Center San Antonio, San Antonio, TX
 Yi Li, Baylor College of Medicine, Houston, TX
 Jafi Lipson, Stanford University, Stanford, CA
 Christopher Lord, Breakthrough Breast Cancer Research Centre, London, UNITED KINGDOM
 Eleftherios P. Mamounas, MD Anderson Cancer Center, Orlando, FL
 David A. Mankoff, University of Pennsylvania, Philadelphia, PA
 Paul Kelly Marcom, Duke University, Durham, NC
 Suleiman A. Massarweh, University of Kentucky, Lexington, KY
 Polly Niravath, Baylor College of Medicine, Houston, TX
 Edith A. Perez, Mayo Clinic, Jacksonville, FL
 Charles M. Perou, University of North Carolina, Chapel Hill, NC
 Martine J. Piccart, Jules Bordet Institute, Brussels, BELGIUM
 Lori J. Pierce, University of Michigan Medical School, Ann Arbor, MI
 Lajos Pusztai, Yale Cancer Center, New Haven, CT
 Susan W. Rafté, Pink Ribbons Project, Houston, TX
 Peter M. Ravdin, UT Health Science Center, San Antonio, TX
 Abram Recht, Beth Israel Deaconess Medical Center, Boston, MA
 Jorge Reis-Filho, Memorial Sloan-Kettering Cancer Center, New York, NY
 Andrea Richardson, Dana-Farber Cancer Institute, Boston, MA
 Mothaffar Rimawi, Baylor College of Medicine, Houston, TX
 David Rimm, Yale University School of Medicine, New Haven, CT
 Hope S. Rugo, University of California, San Francisco, CA
 Rachel Schiff, Baylor College of Medicine, Houston, TX
 Emily Sedgwick, Baylor College of Medicine, Houston, TX
 Victoria Seewaldt, Duke University Medical Center, Durham, NC
 George W. Sledge, Jr, Stanford University, Stanford, CA
 Barbara L. Smith, Massachusetts General Hospital, Boston, MA
 Ian Smith, The Royal Marsden Hospital, London, UNITED KINGDOM
 Lawrence J. Solin, Albert Einstein Medical Center, Philadelphia, PA
 Christos Sotiriou, Institute Jules Bordet, Brussels, BELGIUM
 W. Fraser Symmans, UT MD Anderson Cancer Center, Houston, TX
 Nicholas Turner, Royal Marsden Hospital, Institute of Cancer Research, London, UNITED KINGDOM
 Laura J. van 't Veer, University of California, San Francisco, CA
 Juan Vera, Baylor College of Medicine, Houston, TX
 Giuseppe Viale, University of Milan, Milano, ITALY
 Shaomeng Wang, University of Michigan, Ann Arbor, MI
 Thomas Westbrook, Baylor College of Medicine, Houston, TX
 Gary Whitman, UT MD Anderson Cancer Center, Houston, TX
 Antonio C. Wolff, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD
 Douglas Yee, University of Minnesota, Minneapolis, MN
 Richard Zellars, Johns Hopkins University School of Medicine, Baltimore, MD
 Xiang Zhang, Baylor College of Medicine, Houston, TX

HOTEL MAP & INFORMATION



Downtown San Antonio

FREE SHUTTLE BUS

Shuttle buses will operate December 10 through December 14 between official Symposium hotels and the convention center at no charge.

The Marriott Rivercenter – Riverwalk is the official Headquarters Hotel of the San Antonio Breast Cancer Symposium.

Hotels	Hotel Rates* single/double	Hotels	Hotel Rates* single/double
A Courtyard by Marriott San Antonio Riverwalk 207 N. St. Mary's	\$204/\$204	O Hotel Indigo San Antonio Riverwalk 830 N St Mary's St.	\$149/\$149
B Wyndham San Antonio Hotel - Riverwalk <i>(formerly Crowne Plaza San Antonio)</i> 111 E. Pecan St.	\$182/\$182	P Hotel Valencia Riverwalk 150 E. Houston St.	\$237/\$237
C Drury Inn and Suites 201 N. St. Mary's	\$166/\$166	Q Hyatt Place San Antonio/Riverwalk 601 S. St. Mary's St.	\$214/\$214
D Drury Plaza 105 S. St. Mary's	\$166/\$166	R Hyatt Regency San Antonio 123 Losoya St.	\$237/\$237
E El Tropicano Riverwalk Hotel 110 Lexington Ave.	\$126/\$126	S La Quinta Inn & Suites Convention Center 303 Blum St.	\$155/\$155
F Embassy Suites San Antonio Riverwalk 125 E. Houston St.	\$214/\$214	T Marriott Rivercenter 101 Bowie St.	\$240/\$240
G Emily Morgan Hotel 705 E. Houston St.	\$179/\$179	U Marriott Riverwalk 889 E. Market St.	\$240/\$240
H Fairfield Inn & Suites Downtown Alamo Plaza 422 Bonham St.	\$121/\$121	V Mokara Hotel 212 W. Crockett St.	\$388/\$388
I Grand Hyatt San Antonio 600 E. Market St.	\$250/\$250	W Omni La Mansion del Rio Hotel 112 College St.	\$235/\$235
J Hampton Inn Downtown 414 Bowie St.	\$123/\$123	X Residence Inn by Marriott – Alamo Plaza/Downtown 425 Bonham St.	\$168/\$168
K Hilton Palacio del Rio 200 S. Alamo St.	\$237/\$237	Y Sheraton Gunter Hotel 205 E. Houston St.	\$200/\$200
L Historic Menger Hotel 204 Alamo Plaza	\$172/\$172	Z SpringHill Suites Downtown Alamo Plaza 411 Bowie St.	\$132/\$132
M Holiday Inn Riverwalk 217 N. St. Mary's	\$170/\$170	* Westin Riverwalk Hotel 420 W. Market St.	\$237/\$237
N Hotel Indigo at the Alamo 105 N. Alamo Plaza	\$179/\$179	# St. Anthony Hotel 300 E. Travis St.	\$189/\$189

Hotels are added throughout the year. Please visit www.sabcs.org (click on "Housing") for the most recent list.
*(exclusive of tax & meals) Rates are subject to availability.

**GET WHAT YOU WANT.
BOOK TODAY.**

Call: 800-243-1206 (US) 312-527-7300 (INTERNATIONAL)
Fax: 888-726-9290 or 404-393-3172
Online: www.sabcs.org Email: sabcs@onpeak.co

HOTEL INSTRUCTIONS

For best availability and immediate confirmation, make your reservation via the Symposium website www.sabcs.org.

Housing by **onPeak**


MAKING YOUR RESERVATION

You can book your SABCS housing in one of 5 EASY WAYS:

1. Online – www.sabcs.org

The most efficient way to book specially discounted hotel rooms is online, with real-time hotel reservation processing.

5 Simple Steps



2. Email – sabcs@onpeak.co

Please provide all the information required on the enclosed Hotel Request Form or download the Hotel Request Form from www.sabcs.org and send as an attachment.

3. Fax

Return the housing form (or download a printable form from www.sabcs.org) to **888-726-9290** or **404-393-3172**. **Please note: Incomplete forms cannot be processed.**

4. Mail

Return the hotel form to:

SABCS Housing Bureau

c/o onPeak

240 Peachtree Street, Suite 22-S-22

Atlanta, Georgia 30303

5. Phone

800-243-1206 (US & Canada)

312-527-7300 (International)

DEADLINES

Individual: November 15, 2013

Group Room Block Requests:

Rooming list: September 27, 2013

Confirmation of Master Account/Credit Card

Authorization: September 27, 2013

All reductions after September 27, 2013 are non-refundable.

Group/Agency Block Reduction: September 27, 2013

Last Day for Changes: November 15, 2013

Reserve your room at one of the official 2013 SABCS hotels while discounted hotel rooms are available. All hotel reservations must be completed by this deadline to receive discounted hotel rates, so don't delay! Book your hotel today to secure one of your top hotel preferences. All rates are based on the number of people staying in room and are subject to 16.75% occupancy tax (subject to change). Special requests cannot be guaranteed; however, the hotels will do their best to honor all requests. Hotels will assign specific room types upon check in, based on availability. Reservations are accepted on a first come, first served basis. A two night room rate + tax advance deposit by credit card valid through December 2013, check or wire transfer is required.

ACKNOWLEDGEMENTS

An acknowledgement of your hotel reservation will be sent to you immediately via email upon completion of the online process or within 72 hours for reservations received via phone, fax or mail.

DEPOSITS

Reservations will be processed on a first come, first served basis and a **two night room rate plus tax** deposit by credit card (expiration date valid through December 2013) check or wire transfer is required. Wire transfer information is provided on Group/Agency Housing form and can be provided by request to sabcs@onpeak.co or by fax to **888-726-9290** or **404-393-3172**. Please note this form is required for sending deposit funds via a wire transfer. All deposits for individual reservations are due when the initial reservation is made. Card may be charged 30 days prior to arrival by the HOTEL. All new reservations, changes, substitutions and cancellations must be made through onPeak. Please refer to your hotel confirmation for individual cancellation and deposit policies. Group/Agency hotel requests must be accompanied by a credit card with an expiration date valid during the time of stay or an advance deposit of two nights room & tax per room (non-refundable after September 27, 2013) paid by check or wire transfer only.

GROUP RESERVATIONS

Room block requests are limited to a maximum of 50 rooms per hotel with the exception of the Grand Hyatt and the Marriott Rivercenter where requests are limited to a maximum of 100 rooms. To obtain a Group Housing Request form, please contact onPeak at sabcs@onpeak.co or fax to **888-726-9290** or **404-393-3172**. You can also download and print a Group Housing Request form from www.sabcs.org. Please be sure to note SABCS policies and deadline dates provided on the Group/Agency Housing Form. Group Sub-Block Confirmation letters will be sent to you by email. Please be sure to note SABCS policies and deadline dates.

Group/Agency reservations require a credit card with a valid expiration date during the time of stay or an advance deposit of two nights room & tax per room (non-refundable after 9/27/13) paid by check or wire transfer. This deposit or credit card information must be received within 30 days or your rooms will be released. A financial commitment to utilize 100% of the total room nights is required. Rooms may be released prior to September 27, 2013, however all reductions after September 27, 2013 are nonrefundable. Credit Card authorizations or establishment of a Master Account with the applicable hotels is required by September 27, 2013. Please see the Group/Agency Request form for further information.

Please note the following group reservations policies:

- For group reservations from travel agencies and other service providers, an original, signed, Agent of Record letter must be sent to OnPeak by the client. Only originals on client letterhead are acceptable.
- Group sub-blocks cannot be re-sold to third parties or subcontractors. Companies who do so will be permanently barred from participation in SABCS, and all authorized SABCS vendors and hotels will be notified of same. Re-sold rooms are subject to cancellation and no refund will be issued.
- Units for suite parlors and each connecting bedroom must be deducted from the current room block. All suites must be approved by SABCS.

HOTEL REQUEST FORM

1 HOTEL SELECTION

Please list your top three hotel selections. If choices are not available, we reserve the right to choose a hotel for you based upon availability.

1. _____ Rewards Number
2. _____ Rewards Number
3. _____ Rewards Number

Check here if you need an ADA accessible room and may require assistance from hotel in event of an emergency.

2 ROOM INFORMATION

Please supply names of all persons to occupy room(s) and type of room. If more than 2 rooms are required, please copy this form. **IMPORTANT NOTE!** For groups of 10 or more you must fill out the Group/Agency Hotel Request form found at www.sabcs.org.

Room #1: _____

- Single Double-1 bed Double-2 beds
 Triple Smoking Non-smoking
 Quad

Room #2: _____

- Single Double-1 bed Double-2 beds
 Triple Smoking Non-smoking
 Quad

Arrival Date (mm-dd-yy): ____/____/____

Departure Date (mm-dd-yy): ____/____/____

3 DEPOSIT INFORMATION

Payment Guarantee

No charges are incurred at the time of booking, however, a payment guarantee is required to hold your reservation in the amount of two night's stay at the confirmed hotel plus current tax of 16.75%, subject to change. The hotel will charge deposit up to 30 days prior to arrival to the credit card provided. Please refer to your confirmation for full details, which may vary per hotel.

Guarantee with Credit Card

Card Number _____

Month _____ Year _____ VS MC AMX DS

Name as it appears on the card _____

Signature _____

My signature above authorizes the assigned hotel to charge my credit card for the deposit amount of two night's room and tax.

Guarantee with Check

Company checks are accepted to reserve rooms but must accompany this form and be received no later than **November 15, 2013**. Two nights room rate plus tax (currently 16.75%, subject to change) will be required to guarantee the reservation. Make checks payable to **onPeak, LLC**. Mail to: 2013 San Antonio Breast Cancer Symposium c/o onPeak, 350 N. Clark St, Suite 200, Chicago, IL 60654.

Deposit by Wire Transfer

Deposits can be applied by a Wire Transfer. Wire Transfer information is provided upon request to sabcs@onpeak.co or fax to 888-726-9290 or 404-393-3172. This is a **required** form if you are sending funds by a wire transfer. Two nights room rate plus tax will be required to guarantee the reservation.

Cancellation Policy

Individual cancellation based on individual hotel policy. Guests may refer to the policy listed on confirmation.

2013 San Antonio Breast Cancer Symposium
December 10–14, 2013
Henry B. Gonzalez Convention Center
San Antonio, Texas
DEADLINE: November 15, 2013

5 EASY WAYS TO MAKE A HOTEL RESERVATION

- 1. Online at:** www.sabcs.org
- 2. Email:** sabcs@onpeak.co
- 3. Mail:** SABCS Housing Bureau
c/o onPeak
240 Peachtree Street, Suite 22-S-22
Atlanta, Georgia 30303
- 4. Fax:** 888-726-9290 or 404-393-3172
- 5. Phone:** 800-243-1206 (US and Canada)
312-527-7300

Please note: Incomplete forms cannot be processed.

MUST BE FILLED OUT

4 CONFIRMATION

You should expect to receive a confirmation within 72 hours if faxing this form to onPeak. If you do not, please contact onPeak.

Send confirmation to: (Please print clearly)

The following information is required for completion of reservation.

Contact Name

Company Name

Address 1

Address 2

City

State

Zip

Country

Telephone Number, with country and city codes

Fax Number, with country and city codes

Email

Hotel reservations for the San Antonio Breast Cancer Symposium opened on March 4, 2013.
For best availability and immediate confirmation, make your reservation via the Symposium website www.sabcs.org.
Faxed housing requests will take 72 hours to process.

REGISTRATION METHODS

Everyone must register in order to attend.

Online: www.sabcs.org

Fax: 210-450-1560

If you register via fax, please DO NOT also mail a copy, as duplicate charges may occur.

Mail: SABCS Registration
c/o UT Health Science Center
7979 Wurzbach Rd, MC 8224
San Antonio, TX 78229 USA

NATIONAL PHYSICIAN IDENTIFIER NUMBER (for USA MDs only)

The 2010 federal Patient Protection and Affordable Care Act (PPACA) requires most of our exhibitors to log encounters in their exhibit booth with US physicians by collecting each National Physician Identifier Number. In order to assist our exhibitors in this task SABCS will incorporate the number in the bar code on each US physician's Symposium badge.

Please note that the Physician Identifier Number is required in order for USA MDs to complete their Symposium registration, whether registering as an individual or part of a group registration.

SYMPOSIUM BADGES WILL BE MAILED TO PRE-REGISTRANTS

BEGINNING OCTOBER 15. Upon arrival at the Symposium, please present your badge at the "PRE-REGISTERED WITH BADGE" desk in the convention center (Bridge Hall) in order to receive your Symposium materials and badge holder.

PAYMENT

Payment must be in U.S. Currency, and checks must be drawn on a U.S. bank.

DEADLINES

Discounted pre-registration ends October 31.

Pre-registration ends November 15.

On site registration opens December 10.

CANCELLATION POLICY

Please send written notice of cancellation by fax to 210-450-1560 or email sabcs@uthscsa.edu.

Cancellations received on or before November 15 will be refunded less the following processing fees:

\$75 Regular Registration

\$20 Resident or Postdoctoral Fellows

\$20 Patient Advocate

Cancellations received after November 15 are not refundable.

NAME CHANGE POLICY

Please send written notice of name changes by fax to 210-450-1560 or by email to sabcs@uthscsa.edu.

All name changes after November 15 will be processed on site.

MEALS

Lunch tickets for 2013 SABCS are offered for either

1. \$14.00: Boxed lunch and a soda or water; redeemable at the Express Lunch area located in Exhibit Hall C.
2. \$18.00: A hot item, soda or water and a dessert; redeemable at the Food Court located in Exhibit Hall B.

No refund or partial refund will be issued for a ticket or for a partial redemption of a ticket.

Tickets can be purchased in advance for individuals & groups.

Continental breakfast, evening poster sessions, receptions & beverages are provided free of charge.

CONFIRMATION

Please provide an email address when you register, regardless of registration method. It will be used to confirm your registration. A second email address is requested to send you the CME/Evaluation link, and to update you on any future developments regarding the Symposium.

SABCS will send written confirmation within 10 days of receipt of the completed registration information. If you do not receive your confirmation within this time frame please contact us at sabcs@uthscsa.edu.

REGISTRATION QUESTIONS

Phone: 210-450-1550

Fax: 210-450-1560

Email: sabcs@uthscsa.edu

MEDIA REGISTRATION

Valid credentials are required of every journalist in order to complete registration. These credentials include an official press identification (business card, press pass, etc) and two bylined articles (or a copy of the masthead if articles are not bylined), or a letter of assignment. See <http://sabcs.org/Registration/index.asp> for Media Registration form and further instructions.

GROUP REGISTRATION INSTRUCTIONS

A minimum of 5 people is required for group registration.

Group Registration Deadline: November 15, 2013

Do not use Group Contact's address, telephone, fax or email for individual members of your group. Complete information for all members of each group **must be** received to insure proper credentials, as well as CME login information and individual receipt of important post-Symposium materials. This information must include each person's:

- institution
- address
- city
- state or province, if applicable
- telephone
- fax
- email
- National Physician Identifier Number (for USA MDs only)

REGISTRATION METHOD

Online

You can register and manage group members utilizing a special web registration system designed exclusively for group registrations.

The group registration contact must register and apply for a group ID and password prior to registering any group members. You may register as the contact by contacting the SABCS office for the Group Contact Registration form at sabcs@uthscsa.edu.

Within five (5) business days of receipt of the group contact information, you will be provided your group ID number and password by return email.

Once you have received your ID number and password, you will be able to register and manage your group at www.sabcs.org.

If you have any questions please email them to:

sabcs@uthscsa.edu

SPREADSHEETS WILL NOT BE ACCEPTED.

CONFIRMATION

SABCS will send all Group Contacts or individual group members written confirmations within 10 days of receipt of the completed registration information. If you do not receive your confirmations within this time frame you may contact SABCS by fax at 210-450-1560 or email sabcs@uthscsa.edu

ON-SITE CHECK IN

An on-site representative is required for your group. If an on-site representative is not designated, group registration will not be accepted.

The On-Site Group Representative is responsible for the pickup and distribution of Symposium badges and materials to group members.

No credentials will be mailed to group registrants in advance of the meeting.

Prior to the Symposium, the Group Representative will be contacted by the Symposium office to set an appointment for Monday, December 9, or Tuesday, December 10. No appointments are available on any other dates. At that appointment the Group Representative will pick up badges and materials for all group members and will also have the opportunity to address changes, cancellations, etc, with Symposium staff.

CANCELLATION POLICY

Please send written notice of cancellation by fax to 210-450-1560 or email sabcs@uthscsa.edu.

Cancellations received on or before November 15 will be refunded less the following processing fees:

- \$75 Regular Registration
- \$20 Resident or Postdoctoral Fellows
- \$20 Patient Advocate

Cancellations received after November 15 are not refundable.

NAME CHANGE POLICY

Please send written notice of name changes by fax to 210-450-1560 or email sabcs@uthscsa.edu.

All name changes after November 15 will be processed on site.

Online: www.sabcs.org

Email Group Registration to: sabcs@uthscsa.edu

Groups are required to complete the SABCS group housing process in order for group Symposium registration to be confirmed. See page 21 for information regarding group housing and visit www.sabcs.org to complete and submit the group housing request form.

Cancellation of group housing will result in cancellation of group registration.

GROUP REGISTRATION CONTACT FORM

FOR OFFICE USE ONLY • Group ID Code

Group Registration Deadline: November 15, 2013 2013 San Antonio Breast Cancer Symposium

1 GROUP IDENTITY

Number of persons in the group (must have at least 5) _____

Group's Corporate Sponsor _____

2 REGISTRATION METHOD

Online The group registration contact must register and apply for a group ID and password prior to registering any group members. You may register as the contact by faxing a completed Group Registration Contact Form to the facsimile number indicated on the form. Within five (5) business days of receipt of the group contact information, you will be provided your group ID number and password by return email. Once you have received your ID number and password, you will be able to register and manage your group at www.sabcs.org.

SPREADSHEETS WILL NOT BE ACCEPTED.

3 GROUP CONTACT INFORMATION

If Group Contact will attend the Symposium, he/she must register and pay along with other Group members.

Contact Name

Company or Agency Name

Address

City State or Province Postal or ZIP Code

Country

Phone Number (country code + city or area code + number)

FAX Number (country code + city or area code + number)

Email Address (Either fax number or Email is required)

4 ON-SITE GROUP REPRESENTATIVE

An on-site representative is required for your group. If an on-site representative is not designated, group registration will not be accepted.

Contact Name

Company or Agency Name

Address

City State or Province Postal or ZIP Code

Country

Phone Number (country code + city or area code + number)

FAX Number (country code + city or area code + number):

Email Address (Either fax number or Email is required):

5 GROUP PAYMENT TYPE (No Purchase Orders)

- Check/Money Order/Draft.
(Make payable to UTHSCSA #151794) Tax ID: 74-1586031
- Wire Transfer, your bank to ours. Add \$30 to total for transfer fees

Instructions for wire transfer will be sent to you by email after your registration is received by SABCS.

- American Express Master Card Visa Discover

Credit Card Number _____

Expiration Date (MM/YY) _____

Cardholder Name _____

Signature _____

6 SABCS ONLINE RESOURCES

The 2013 SABCS Abstract Book will be published in January 2014 as a special online citable supplement to the AACR journal *Cancer Research*. Each SABCS registrant will receive a log-in & password which will allow access to SABCS abstracts, slides & posters online. Attendees will receive their materials at check-in on site.

7 REGISTRATION FEE

Through October 31, 2013: \$450
Effective November 1, 2013: \$600
Wire Transfer Fee \$30 (if applicable)
See Advance Registration form for additional registration fees.

Lunch Tickets

- Lunch tickets for 2013 SABCS are offered for either
1. \$14.00: Boxed lunch and a soda or water; redeemable at the Express Lunch area located in Exhibit Hall C.
 2. \$18.00: A hot item, soda or water and a dessert; redeemable at the Food Court located in Exhibit Hall B.

No refund or partial refund will be issued for a ticket or for a partial redemption of a ticket.

8 CONFIRMATIONS

Send registration confirmations to Group Contact to individuals

FAX THIS FORM TO 210-450-1560, or mail to:

SABCS c/o UT Health Science Center
7979 Wurzbach Road, MC 8224
San Antonio, TX 78229

CANCELLATIONS POLICY

Cancellations must be in writing and received by November 15.

NAME CHANGES POLICY

Changes must be made in writing and received by November 15. After November 15, name changes must be made on-site.

CANCELLATION REFUNDS

Cancellations received on or before November 15 will be refunded less a \$75.00 Processing Fee. Cancellations received after November 15 are nonrefundable.

ADVANCE REGISTRATION FORM

FOR OFFICE USE ONLY • Group ID Code

2013 San Antonio Breast Cancer Symposium • December 10–14, 2013
COMPLETE ALL SECTIONS FULLY • ONE INDIVIDUAL PER FORM

CIRCLE ONE	LAST/FAMILY NAME *	FIRST/GIVEN NAME *	MI
Dr. Prof. Mr. Mrs. Ms. Miss			

DEGREE(s) (or Equivalent)	INSTITUTION, COMPANY, or ORGANIZATION NAME *
MD DO PhD PharmD RN Other _____	

DEPARTMENT

ADDRESS 1 *

ADDRESS 2

CITY *	STATE or PROVINCE *

COUNTRY (if not US) *	ZIP OR POSTAL CODE

TELEPHONE NUMBER, WITH COUNTRY & CITY CODES *	FAX NUMBER, WITH COUNTRY & CITY CODES

CELL PHONE NUMBER

EMAIL ADDRESS for Registration confirmation

EMAIL ADDRESS for CME/Evaluation link

PHYSICIAN IDENTIFIER NUMBER * (IF USA MD)

*** REQUIRED**
PLEASE INCLUDE ME IN THE MAILING LIST FOR PRINTED SABCS PRE-SYMPOSIUM INFORMATION. YES NO

<p>PRIMARY PROFESSIONAL FOCUS (Check ONE only):</p> <p><input type="checkbox"/> Medical Practice</p> <p><input type="checkbox"/> Clinical Research</p> <p><input type="checkbox"/> Basic Research</p> <p><input type="checkbox"/> Epidemiology</p> <p><input type="checkbox"/> Prevention</p> <p><input type="checkbox"/> Translational Research</p> <p><input type="checkbox"/> Other</p>	<p>PRIMARY PROFESSIONAL OCCUPATION (Check ONE only):</p> <table style="width: 100%; border: none;"> <tr> <td style="width: 33%;"> Medical Practice/Clinical Research <input type="checkbox"/> 01 Medical Oncologist <input type="checkbox"/> 02 Surgical Oncologist <input type="checkbox"/> 03 Radiation Oncologist <input type="checkbox"/> 04 General Surgeon <input type="checkbox"/> 05 Gynecologic Oncologist <input type="checkbox"/> 06 Reconstructive Surgeon <input type="checkbox"/> 07 Pathologist <input type="checkbox"/> 08 Radiologist </td> <td style="width: 33%;"> Clinical Geneticist <input type="checkbox"/> 09 Clinical Geneticist <input type="checkbox"/> 10 Oncology Nurse <input type="checkbox"/> 11 Research Nurse <input type="checkbox"/> 12 Data Manager <input type="checkbox"/> 13 Other Physician <input type="checkbox"/> 14 Other Nurse <input type="checkbox"/> 15 Trainee </td> <td style="width: 33%;"> Basic Research <input type="checkbox"/> 20 Laboratory Scientist <input type="checkbox"/> 21 Statistician <input type="checkbox"/> 22 Epidemiologist <input type="checkbox"/> 23 Research Assistant <input type="checkbox"/> 25 Trainee </td> <td style="width: 33%;"> Industry <input type="checkbox"/> 30 Corporate Research <input type="checkbox"/> 31 Marketing/Sales <input type="checkbox"/> 32 Industry Nurse <input type="checkbox"/> 33 Pharmaceutical Rep <input type="checkbox"/> 34 Industry PR <input type="checkbox"/> 35 Other Industry </td> <td style="width: 33%;"> Other Profession <input type="checkbox"/> 40 Patient Advocate <input type="checkbox"/> 41 Administrator <input type="checkbox"/> 42 Other PR <input type="checkbox"/> 43 Medical Writer <input type="checkbox"/> 44 Pharmacist <input type="checkbox"/> 45 Other Occupation </td> </tr> </table>	Medical Practice/Clinical Research <input type="checkbox"/> 01 Medical Oncologist <input type="checkbox"/> 02 Surgical Oncologist <input type="checkbox"/> 03 Radiation Oncologist <input type="checkbox"/> 04 General Surgeon <input type="checkbox"/> 05 Gynecologic Oncologist <input type="checkbox"/> 06 Reconstructive Surgeon <input type="checkbox"/> 07 Pathologist <input type="checkbox"/> 08 Radiologist	Clinical Geneticist <input type="checkbox"/> 09 Clinical Geneticist <input type="checkbox"/> 10 Oncology Nurse <input type="checkbox"/> 11 Research Nurse <input type="checkbox"/> 12 Data Manager <input type="checkbox"/> 13 Other Physician <input type="checkbox"/> 14 Other Nurse <input type="checkbox"/> 15 Trainee	Basic Research <input type="checkbox"/> 20 Laboratory Scientist <input type="checkbox"/> 21 Statistician <input type="checkbox"/> 22 Epidemiologist <input type="checkbox"/> 23 Research Assistant <input type="checkbox"/> 25 Trainee	Industry <input type="checkbox"/> 30 Corporate Research <input type="checkbox"/> 31 Marketing/Sales <input type="checkbox"/> 32 Industry Nurse <input type="checkbox"/> 33 Pharmaceutical Rep <input type="checkbox"/> 34 Industry PR <input type="checkbox"/> 35 Other Industry	Other Profession <input type="checkbox"/> 40 Patient Advocate <input type="checkbox"/> 41 Administrator <input type="checkbox"/> 42 Other PR <input type="checkbox"/> 43 Medical Writer <input type="checkbox"/> 44 Pharmacist <input type="checkbox"/> 45 Other Occupation
Medical Practice/Clinical Research <input type="checkbox"/> 01 Medical Oncologist <input type="checkbox"/> 02 Surgical Oncologist <input type="checkbox"/> 03 Radiation Oncologist <input type="checkbox"/> 04 General Surgeon <input type="checkbox"/> 05 Gynecologic Oncologist <input type="checkbox"/> 06 Reconstructive Surgeon <input type="checkbox"/> 07 Pathologist <input type="checkbox"/> 08 Radiologist	Clinical Geneticist <input type="checkbox"/> 09 Clinical Geneticist <input type="checkbox"/> 10 Oncology Nurse <input type="checkbox"/> 11 Research Nurse <input type="checkbox"/> 12 Data Manager <input type="checkbox"/> 13 Other Physician <input type="checkbox"/> 14 Other Nurse <input type="checkbox"/> 15 Trainee	Basic Research <input type="checkbox"/> 20 Laboratory Scientist <input type="checkbox"/> 21 Statistician <input type="checkbox"/> 22 Epidemiologist <input type="checkbox"/> 23 Research Assistant <input type="checkbox"/> 25 Trainee	Industry <input type="checkbox"/> 30 Corporate Research <input type="checkbox"/> 31 Marketing/Sales <input type="checkbox"/> 32 Industry Nurse <input type="checkbox"/> 33 Pharmaceutical Rep <input type="checkbox"/> 34 Industry PR <input type="checkbox"/> 35 Other Industry	Other Profession <input type="checkbox"/> 40 Patient Advocate <input type="checkbox"/> 41 Administrator <input type="checkbox"/> 42 Other PR <input type="checkbox"/> 43 Medical Writer <input type="checkbox"/> 44 Pharmacist <input type="checkbox"/> 45 Other Occupation		

PLEASE BE SURE TO SCAN OR FAX BOTH SIDES OF THIS FORM WHEN SENDING

THIS PAGE MAY BE PHOTO COPIED

ADVANCE REGISTRATION FORM – CONTINUED

2013 San Antonio Breast Cancer Symposium • December 10–14, 2013

COMPLETE ALL SECTIONS FULLY • ONE INDIVIDUAL PER FORM

REGISTRATION CATEGORY:	(Check One)	
	DISCOUNT <small>before 10/31/2013</small>	FULL PRICE <small>after 10/31/2013</small>
Regular Registration	RRA <input type="checkbox"/> \$450.00	\$600.00
Regular Registration: AACR members	CRA <input type="checkbox"/> \$382.50	\$510.00

AACR member ID: _____

Regular Registration: UTHSCSA & BCM staff & faculty (Valid ID required w/registration)	ST <input type="checkbox"/> \$200.00	\$275.00
MD Resident or Postdoctoral fellow (With valid ID or letter of appointment)	PMA <input type="checkbox"/> \$100.00	\$120.00
PhD Postdoctoral fellow (With valid ID or letter of appointment)	PPA <input type="checkbox"/> \$100.00	\$120.00
Medical Student (Valid ID required w/registration)	SU <input type="checkbox"/> \$ 0.00	\$ 0.00
PhD Student (Valid ID required w/registration)	SU <input type="checkbox"/> \$ 0.00	\$ 0.00
Patient Advocate* (Must provide name of the organization you are representing)	PAA <input type="checkbox"/> \$100.00	\$120.00

Advocate Organization _____

*Contact **Alamo Breast Cancer Foundation** PO Box 780067, San Antonio TX 78278, for Advocate Program information and possible financial assistance. Email sandisues@sbcglobal.net

Are you part of an official Group Registration? No Yes

Provide Group ID Code: _____

REFUNDS: Please send written notice of cancellation by fax to 210-450-1560 or email sabcs@uthscsa.edu. Cancellations received on or before November 15, 2013 will be refunded less processing fees. Cancellations received after November 15, 2013 are non-refundable.

LUNCH TICKETS:

Wed \$14 \$18 Thu \$14 \$18 Fri \$14 \$18

- Lunch tickets for 2013 SABCS are offered for either
1. \$14.00: Boxed lunch and a soda or water, redeemable at the Express Lunch area located in Exhibit Hall C.
 2. \$18.00: A hot item, soda or water and a dessert redeemable at the Food Court located in Exhibit Hall B.

No refund or partial refund will be issued for a ticket or for a partial redemption of a ticket.

Total for Lunch Tickets.....\$ _____

Total for Registration Fee.....\$ _____

Wire Transfer Fee \$30 (if applicable).....\$ _____

TOTAL AMOUNT DUE.....\$ _____

Payment must be in US Currency. • Checks must be drawn on US bank.

MAIL TO: SABCS Registration c/o UT Health Science Center
7979 Wurzbach Rd, MC 8224
San Antonio, TX 78229

OR FAX TO: 210-450-1560

If you need special assistance, contact the Symposium office at 210-450-1550 or sabcs@uthscsa.edu.

Registration inquiries may be directed to: sabcs@uthscsa.edu or by phone 210-450-1550.

PAYMENT TYPE: (No Purchase Orders.)

- Payment is being made by Group Contact.
- Check/Money Order/Draft.
(Make payable to UTHSCSA #151794)
- Wire Transfer, your bank to ours. Add \$30 to the total for transfer fees.

Instructions for wire transfer will be sent to you by Email after your registration is received by SABCS.

- AMEX MasterCard Visa Discover

Credit Card Number

Exp Date (MM/YY)

Cardholder Name

Signature

CREDIT CARD BILLING INFORMATION:

Address Line 1

Address Line 2

City

State/Province

ZIP Code

Non-US Province, Country

THIS PAGE MAY BE PHOTO COPIED

ADVANCE REGISTRATION FORM – PRESS/MEDIA

2013 San Antonio Breast Cancer Symposium • December 10–14, 2013

COMPLETE ALL SECTIONS FULLY • ONE INDIVIDUAL PER FORM

Please submit this form with your credentials. **CREDENTIALS ARE REQUIRED** for approval of Press/Media registrations. For further information contact Lauren Riley, American Association for Cancer Research, lauren.riley@aacr.org or 215-446-7155.

CREDENTIALS:

Press & media staff: Company Press ID and two bylined articles or a copy of the masthead.

Freelance: Signed letter of assignment on company letterhead.

Fax to:

Lauren Riley, American Association for Cancer Research, 215-446-7291

Mail to:

Lauren Riley
American Association for Cancer Research
615 Chestnut Street
17th Floor
Philadelphia, PA 19106

CIRCLE ONE Dr. Prof. Mr. Mrs. Ms. Miss	LAST/FAMILY NAME	FIRST/GIVEN NAME	MI
INSTITUTION, COMPANY, or ORGANIZATION NAME			
DEPARTMENT			
ADDRESS 1			
ADDRESS 2		CITY	
STATE or PROVINCE		COUNTRY (if not US)	
ZIP OR POSTAL CODE	TELEPHONE NUMBER, WITH COUNTRY & CITY CODES	FAX NUMBER, WITH COUNTRY & CITY CODES	
EMAIL ADDRESS			

If you need special assistance, contact the Symposium office at 210-450-1550 or sabcs@uthscsa.edu.

CANCELLATION

Please notify SABCS via fax 210-450-1560 or email sabcs@uthscsa.edu if you must cancel your registration.

SABCS PRESSROOM

SABCS maintains a pressroom located on the concourse level of the convention center, directly upstairs from our sessions. Audio and video of speakers and slides are transmitted to the pressroom. Facilities include photocopier, fax machine, and desk space with high-speed internet connection. Daily continental breakfast and coffee service are provided in the pressroom free of charge.

CAREER DEVELOPMENT FORUM REGISTRATION FORM

Career Development Forum: A Networking Session for Young Investigators

Tuesday, December 10, 2013 • 12:00 pm–1:45 pm (Time and date subject to change)

Henry B. Gonzalez Convention Center

San Antonio, TX

**Registration Deadline:
November 15, 2013**

- The session is open to early-career scientists, defined as graduate students, postdoctoral or clinical fellows, or medical students and residents, who are registered attendees of the 2013 SABCS.
- Space in the workshop is limited to 300 participants; registrations will be accepted on a first-come, first-served basis and are free of charge.

REGISTRATION FORM (ALL FIELDS REQUIRED)

FIRST/GIVEN NAME		MIDDLE NAME	LAST/FAMILY NAME
DEGREE		TITLE/POSITION	
DEPARTMENT			
INSTITUTION			
INSTITUTION ADDRESS 1			
INSTITUTION ADDRESS 2		CITY	
STATE or PROVINCE		COUNTRY	
ZIP OR POSTAL CODE	TELEPHONE NUMBER, WITH COUNTRY & CITY CODES		FAX NUMBER, WITH COUNTRY & CITY CODES
CELL PHONE NUMBER, WITH COUNTRY & CITY CODES			
EMAIL ADDRESS			

DEMOGRAPHIC INFORMATION

(Optional, for program development purposes only. Information will be kept confidential)

- Gender: Male Female
- Are you a clinician-scientist: Yes No
- Race/Ethnicity:
- Caucasian/White
 - African-American/Black
 - Asian
 - Hispanic
 - Native Pacific Islander
 - Native American
 - Alaskan Native
 - Other

PLEASE RETURN TO:

SABCS Fax 210-450-1560
sabcs@uthscsa.edu

Confirmations will be sent via email within 5 working days



NOTES

We are proud to acknowledge the following for their contributions to and generous support of our program (at press time).

PREMIER

Genentech, A Member of the Roche Group

ANGEL

AbbVie
Genomic Health, Inc.
Novartis Oncology

PATRON

Eli Lilly and Company
nanoString
Novartis Oncology

MAJOR SUPPORTER

Amgen
AstraZeneca
Celgene Corporation
Eisai, Inc.
GE Healthcare (Clariant)
Pfizer
Teva Oncology

CONTRIBUTORS

Agendia, Inc.
GeneDx
Myriad Genetic Laboratories, Inc.

DONORS

Ambry Genetics
Atossa Genetics, Inc.
Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals
BioMed Central
Boehringer Ingelheim Pharmaceuticals, Inc.
Bristol-Myers Squibb
CareFusion
Carl Zeiss Meditec, Inc.
Clinical Oncology News
Dilon Diagnostics
Elekta, Inc.
Endomagnetics Ltd.
Genoptix Medical Laboratory
InVita
Phenogen Sciences
Physicians' Education Resource, LLC
Provista Diagnostics Reference Laboratory
Quest Diagnostics
Theranostics Health, Inc.
Toray Industries, Inc.
Wolters Kluwer Health (Lippincott)

Exhibit Hours

Wednesday, December 11, 2013	11:00 AM – 5:00 PM
Thursday, December 12, 2013	11:00 AM – 5:00 PM
Friday, December 13, 2013	11:00 AM – 5:00 PM

Exhibits will be featured in Exhibit Hall C.

EXHIBITOR LIST (AT PRESS TIME)

AbbVie	Genomic Health, Inc.
Agendia, Inc.	Genoptix Medical Laboratory
Alamo Breast Cancer Foundation	GlaxoSmithKline Commercial
Ambry Genetics	GlaxoSmithKline Oncology
American Cancer Society	Harborside Press
AACR - American Association for Cancer Research	Inspire
American Society of Clinical Oncology (ASCO)	InVita
Amgen	Janssen Diagnostics, LLC
Atossa Genetics, Inc.	Lilly Oncology
Bayer HealthCare Pharmaceuticals/ Onyx Pharmaceuticals	Lilly Oncology on Canvas
BioMed Central	MedImmune
Boehringer Ingelheim Pharmaceuticals, Inc.	Myriad Genetic Laboratories, Inc.
Breast Cancer Action	nanoString Technologies, Inc.
Bristol-Myers Squibb	Novartis Oncology
CareFusion	Pfizer Oncology
Care Wise Medical Products	Phenogen Sciences
Carl Zeiss Meditec, Inc.	Physicians' Education Resource, LLC
Celgene Corporation	Provista Diagnostics Reference Laboratory
Celldex Therapeutics, Inc.	Quest Diagnostics
Clariant	Sharsheret: Your Jewish Community Facing Breast Cancer
Clinical Oncology News	Teva Oncology
DARA BioSciences, Inc.	Theranostics Health, Inc.
Dilon Diagnostics	Toray Industries Inc.
Eisai, Inc.	TRIO (Translational Research in Oncology)
Elekta, Inc.	Wolters Kluwer Health (Lippincott)
Encore Medical Education, LLC "Best of SABCS"	Young Survival Coalition
Endomagnetics, Ltd.	
FORCE: Facing Our Risk of Cancer Empowered	
GeneDx	
Genentech	

SABCS gratefully acknowledges the **John and Editha Kapoor Charitable Foundation** for its generous support.

SABCS wishes to thank Avon Foundation for support of the
Avon Foundation-AACR International Scholar-In-Training Grants.

SABCS gratefully acknowledges Susan G. Komen for the Cure for generous support of **AACR Outstanding Investigator Award for Breast Cancer Research**, and partial support of **The Editha Kapoor Breast Cancer Educational Sessions.**



Cancer Therapy & Research Center
7979 Wurzbach Rd, Suite 600
San Antonio, TX 78229

Non-Profit Organization
U.S. Postage
PAID
Permit 1001
San Antonio, Texas



December 10–14, 2013
San Antonio, Texas USA
www.sabcs.org



Cancer Therapy & Research Center
7979 Wurzbach Rd, Suite 600
San Antonio, TX 78229



December 10–14, 2013
San Antonio, Texas USA
www.sabcs.org